Journal of Pathology and Translational Medicine

Review

HER2 status in breast cancer: changes in guidelines and complicating factors for interpretation: Soomin Ahn, Ji Won Woo, Kyoungyul Lee, So Yeon Park; J Pathol Transl Med. 2020;54(1):34-44. Published online November 6, 2019; DOI: https://doi.org/10.4132/jptm.2019.11.03

38,004 View
1,323 Download
189 Web of Science
187 Crossref

Human epidermal growth factor receptor 2 (HER2) protein overexpression and/or HER2 gene amplification is found in about 20% of invasive breast cancers. It is a sole predictive marker for treatment benefits from HER2 targeted therapy and thus, HER2 testing is a routine practice for newly diagnosed breast cancer in pathology. Currently, HER2 immunohistochemistry (IHC) is used for a screening test, and in situ hybridization is used as a confirmation test for HER2 IHC equivocal cases. Since the American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines on HER2 testing was first released in 2007, it has been updated to provide clear instructions for HER2 testing and accurate determination of HER2 status in breast cancer. During HER2 interpretation, some pitfalls such as intratumoral HER2 heterogeneity and increase in chromosome enumeration probe 17 signals may lead to inaccurate assessment of HER2 status. Moreover, HER2 status can be altered after neoadjuvant chemotherapy or during metastatic progression, due to biologic or methodologic issues. This review addresses recent updates of ASCO/CAP guidelines and factors complicating in the interpretation of HER2 status in breast cancers.

Citations

Citations to this article as recorded by

A Comprehensive Model Outperformed the Single Radiomics Model in Noninvasively Predicting the HER2 Status in Patients with Breast Cancer
Weimin Liu, Yiqing Yang, Xiaohong Wang, Chao Li, Chen Liu, Xiaolei Li, Junzhe Wen, Xue Lin, Jie Qin
Academic Radiology.2025; 32(1): 24. CrossRef
Multiparametric MRI Radiomics With Machine Learning for Differentiating HER2-Zero, -Low, and -Positive Breast Cancer: Model Development, Testing, and Interpretability Analysis
Yongxin Chen, Siyi Chen, Wenjie Tang, Qingcong Kong, Zhidan Zhong, Xiaomeng Yu, Yi Sui, Wenke Hu, Xinqing Jiang, Yuan Guo
American Journal of Roentgenology.2025;[Epub] CrossRef
Cervical Lymph Node Metastasis of Unknown Origin and Remote Primary at a Tertiary Cancer Centre in North India: Case Series with Review of Literature
Kriti Grover, Siddharth Arora, Mansi Dey, Deepti Awasthi, Harshad Sharma, Bibhu Prasad Mishra, Nitesh Mohan, Cheena Garg, Arjun Agarwal
Indian Journal of Otolaryngology and Head & Neck Surgery.2025; 77(1): 424. CrossRef
Pooled clinical trial analyses evaluating outcomes of HER2-low vs HER2-0 expression in patients with metastatic breast cancer following chemotherapy
Elizabeth B. Lamont, Emily Stein, Paolo Tarantino, Sara M. Tolaney, Corinne Ahlberg, Krishna Chinnathambu, Jiezhi Qi, Jackie Bilan, Ruthie Davi, Lisa Ensign
Breast Cancer Research and Treatment.2025; 210(1): 11. CrossRef
Insights into AI advances in immunohistochemistry for effective breast cancer treatment: a literature review of ER, PR, and HER2 scoring
Genevieve Chyrmang, Kangkana Bora, Anup Kr. Das, Gazi N. Ahmed, Lopamudra Kakoti
Current Medical Research and Opinion.2025; 41(1): 115. CrossRef
Prediction of Lung Adenocarcinoma Driver Genes Through Protein–Protein Interaction Networks Utilizing GenePlexus
Fei Yuan, Yu‐Hang Zhang, FeiMing Huang, Xiaoyu Cao, Lei Chen, JiaBo Li, WenFeng Shen, KaiYan Feng, YuSheng Bao, Tao Huang, Yu‐Dong Cai
PROTEOMICS.2025;[Epub] CrossRef
Quantitative expression of estrogen, progesterone and human epidermal growth factor receptor-2 and their correlation with immunohistochemistry in breast cancer at Uganda Cancer Institute
Henry Wannume, Nixon Niyonzima, Sam Kalungi, Julius Boniface Okuni, Tonny Okecha, Edward Kakungulu, Steven Mpungu Kiwuwa, Geoffrey Waiswa, Sylvester Kadhumbula, Monica Namayanja, Martin Nabwana, Jackson Orem, Kenji Fujiwara
PLOS ONE.2025; 20(1): e0311185. CrossRef
Automated Quantification of HER2 Amplification Levels Using Deep Learning
Ching-Wei Wang, Kai-Lin Chu, Ting-Sheng Su, Keng-Wei Liu, Yi-Jia Lin, Tai-Kuang Chao
IEEE Journal of Biomedical and Health Informatics.2025; 29(1): 333. CrossRef
CAR-macrophage therapy for HER2-overexpressing advanced solid tumors: a phase 1 trial
Kim A. Reiss, Mathew G. Angelos, E. Claire Dees, Yuan Yuan, Naoto T. Ueno, Paula R. Pohlmann, Melissa L. Johnson, Joseph Chao, Olga Shestova, Jonathan S. Serody, Maggie Schmierer, Madison Kremp, Michael Ball, Rehman Qureshi, Benjamin H. Schott, Poonam Son
Nature Medicine.2025; 31(4): 1171. CrossRef
Human Cytomegalovirus Infection and Breast Cancer: A Literature Review of Clinical and Experimental Data
Rancés Blanco, Juan P. Muñoz
Biology.2025; 14(2): 174. CrossRef
An antibody-photosensitiser bioconjugate overcomes trastuzumab resistance in HER2-positive breast cancer
Mireia Jordà-Redondo, Ana Piqueras, Ana Castillo, Pedro Luis Fernández, Roger Bresolí-Obach, Lidia Blay, Joan Francesc Julián Ibáñez, Santi Nonell
European Journal of Medicinal Chemistry.2025; 290: 117511. CrossRef
Dynamic HER2-low status among patients with triple negative breast cancer (TNBC) and the impact of repeat biopsies
Yael Bar, Geoffrey Fell, Aylin Dedeoglu, Natalie Moffett, Neelima Vidula, Laura Spring, Seth A. Wander, Aditya Bardia, Naomi Ko, Beverly Moy, Leif W. Ellisen, Steven J. Isakoff
npj Breast Cancer.2025;[Epub] CrossRef
Clinical significances of RPL15 gene expression in circulating tumor cells of patients with breast cancer
Ying Zhuang, Keli Su, Shushu Liu, Wei Fan, Huijuan Lv, Wei Zhong
Biomedical Reports.2025; 22(5): 1. CrossRef
Advancing Breast Cancer Treatment: The Role of Immunotherapy and Cancer Vaccines in Overcoming Therapeutic Challenges
Marco Palma
Vaccines.2025; 13(4): 344. CrossRef
Complete preclinical evaluation of the novel antibody mimetic Nanofitin-IRDye800CW for diverse non-invasive diagnostic applications in the management of HER-2 positive tumors
Margherita Iaboni, Federico Crivellin, Francesca Arena, Francesca La Cava, Alessia Cordaro, Francesco Stummo, Daniele Faletto, Simon Huet, Leo Candela, Jessy Pedrault, Eugenia R. Zanella, Andrea Bertotti, Francesco Blasi, Alessandro Maiocchi, Luisa Poggi,
Scientific Reports.2025;[Epub] CrossRef
New insights on Galectin-9 expression in cancer prognosis: An updated systemic review and meta-analysis
Chun Yan So, Yusong Li, Kwan Ting Chow, Xiaosheng Tan
PLOS ONE.2025; 20(3): e0320441. CrossRef
Role of artificial intelligence –based machine learning model in predicting HER2/neu gene status in breast cancer
Ghada Mohamed, Omar Hamdy, Anwar Alkallas, Youssef Tahoun, Mohammed Mohammed Gomaa, Inas Moaz, Ahmed Orabi, Yasmine Hany elzohery, AL-Shimaa Zakaria, Mahitab Ibrahim Eltohamy
Pathology - Research and Practice.2025; 270: 155927. CrossRef
HER2 mRNA Score From Quantitative ERBB2 mRNA Expression of Oncotype Dx
Hyunwoo Lee, Jai Min Ryu, Se Kyung Lee, Byung Joo Chae, Jonghan Yu, Jeong Eon Lee, Seok Won Kim, Seok Jin Nam, Yoon Ah Cho, Eun Yoon Cho
American Journal of Surgical Pathology.2025; 49(8): 807. CrossRef
Neratinib and metformin: A novel therapeutic approach against HER2-Positive Breast Cancer
Hadeel Kheraldine, Arij Fouzat Hassan, Sumayyah Saeed, Maysaloun Merhi, Jericha Miles Mateo, Monika Ulamec, Melita Peric-Balja, Semir Vranic, Hamda Al-Thawadi, Ala-Eddin Al Moustafa
Biomedicine & Pharmacotherapy.2025; 187: 118034. CrossRef
Machine learning prediction of HER2-low expression in breast cancers based on hematoxylin–eosin-stained slides
Jun Du, Jun Shi, Dongdong Sun, Yifei Wang, Guanfeng Liu, Jingru Chen, Wei Wang, Wenchao Zhou, Yushan Zheng, Haibo Wu
Breast Cancer Research.2025;[Epub] CrossRef
Predicting sentinel lymph node metastatic burden with intravoxel incoherent motion diffusion-weighted imaging and dynamic contrast-enhanced magnetic resonance imaging in clinical early-stage breast cancer patients
Mingli Jin, Fang Xiao, Qi Zhao, Ying Jiang, Zhihua Pan, Zhicai Duan, Juxi Jiang, Miaoqi Zhang, Jian Shu
Magnetic Resonance Imaging.2025; 121: 110397. CrossRef
HbA1c levels and breast cancer prognosis in women without diabetes
Jonas Busk Holm, Jens Meldgaard Bruun, Peer Christiansen, Reimar Wernich Thomsen, Jan Frystyk, Deirdre Cronin-Fenton, Signe Borgquist
BMC Cancer.2025;[Epub] CrossRef
Clinical Outcomes in Early-Stage HER2-Low and HER2-Zero Breast Cancer: Single-Center Experience
Jamshid Hamdard, Mehmet Haluk Yücel, Harun Muğlu, Özgür Açıkgöz, Aslı Çakır, Ahmet Bilici, Ömer Fatih Ölmez
Journal of Clinical Medicine.2025; 14(9): 2937. CrossRef
Molecular Mechanism of Breast Cancer and Predisposition of Mouse Mammary Tumor Virus Propagation Cycle
Arya Ghosh, Subash C.B. Gopinath
Current Medicinal Chemistry.2025; 32(12): 2330. CrossRef
ASSESSMENT OF RECEPTOR CONVERSION ROLE FOR ADVANCED BREAST CANCER ON THE CHEMORESISTANCE OCCURRENCE
Oleksii V. Movchan, Ivan I. Smolanka, Andriy O. Lyashenko, Anton D. Loboda, Iryna V. Dosenko, Oksana M. Ivankova
Clinical and Preventive Medicine.2025; (3): 56. CrossRef
Combining conventional magnetic resonance imaging (MRI) parameters with clinicopathologic data for differentiation of the three-tiered human epidermal growth factor receptor 2 (HER2) status in breast cancer
W. Liu, C. Liu, Y. Yang, Y. Chen, A. Muhetaier, Z. Lin, Z. Weng, X. Wang, P. Zhang, J. Qin
Clinical Radiology.2025; 86: 106955. CrossRef
IN SILICO STUDY: THE POTENTIAL OF KILEMO (Litsea cubeba) ENDEMIC PLANT FROM KALIMANTAN AS ANTI-BREAST CANCER THROUGH HER2 INHIBITION
Dwi Utami, Tarisha Elmaningtyas Zahro, Khairun Nisa, Muhammad Farid
JIIS (Jurnal Ilmiah Ibnu Sina): Ilmu Farmasi dan Kesehatan.2025; 10(1): 166. CrossRef
Trastuzumab Deruxtecan in Previously Treated HER2-Low Metastatic Breast Cancer: Real-World Multicentric Study in the Portuguese Population
Luísa Soares Miranda, Maria João Sousa, Miguel Martins Braga, Marisa Couto, Isabel Vieira Fernandes, Francisca Abreu, Inês Eiriz, Catarina Lopes Fernandes, Alice Fonseca Marques, Maria Teresa Marques, Raquel Romão, Fernando Gonçalves, Joana Simões, Antóni
Cancers.2025; 17(12): 1911. CrossRef
Factors influencing pathological complete response to neoadjuvant chemotherapy in resectable breast cancer: A retrospective study
Jian Kang, Huifen Xiong, Xiaoliu Jiang, Zhaohui Huang, Yonghong Guo, Yali Cao, Jingxian Ding
Oncology Letters.2025; 30(1): 1. CrossRef
Association of HER2-low with clinicopathological features in patients with early invasive lobular breast cancer: an international multicentric study
Karen Van Baelen, Ha-Linh Nguyen, François Richard, Gitte Zels, Maria Margarete Karsten, Guilherme Nader-Marta, Peter Vermeulen, Luc Dirix, Adam David Dordevic, Evandro de Azambuja, Denis Larsimont, Marion Maetens, Elia Biganzoli, Hans Wildiers, Ann Smeet
Breast Cancer Research.2025;[Epub] CrossRef
Collagenase type IV improves the quality of HER2 fluorescence in situ hybridization for breast cancers
Shang-En Lee, Sheng-Chi Hsu, Tsai-Hsien Hung, Kwai-Fong Ng, Tse-Ching Chen
American Journal of Clinical Pathology.2025; 164(3): 342. CrossRef
Resonant multi-focal scanning super-resolution microscopy with extended depth and field-of-view
Kidan Tadesse, Keyi Han, Wenhao Liu, Oliver S. Lee, Shu Jia
Cell Reports Physical Science.2025; 6(7): 102680. CrossRef
Scalable Nuclei Detection in HER2-SISH Whole Slide Images via Fine-Tuned Stardist with Expert-Annotated Regions of Interest
Zaka Ur Rehman, Mohammad Faizal Ahmad Fauzi, Wan Siti Halimatul Munirah Wan Ahmad, Fazly Salleh Abas, Phaik-Leng Cheah, Seow-Fan Chiew, Lai-Meng Looi
Diagnostics.2025; 15(13): 1584. CrossRef
Molecular landscape of HER2-mutated non-small cell lung cancer in Northeastern Brazil: Clinical, histopathological, and genomic insights
Cleto Dantas Nogueira, Samuel Frota, Huylmer Lucena Chaves, Juliana Cordeiro de Sousa, Guilherme de Sousa Veloso, Francisco Jonathan dos Santos Araujo, Gabriel Barbosa Silva, Samuel Silva Ferreira, Marclesson Santos Alves, Fabio Nasser, Ezequiel Rangel, F
Oncotarget.2025; 16(1): 467. CrossRef
Correlation between CTMP expression levels and resistance to trastuzumab in HER2 + metastatic breast cancer
Mania Makhoul, Maher Saifo, Fariz Ahmad, Jumana Saleh
Discover Oncology.2025;[Epub] CrossRef
The association between body mass index and neoadjuvant chemotherapy response in patients with breast cancer
Jonas Busk Holm, Stine Blaabjerg Skovbjerg, Hanne Melgaard Nielsen, Peer Christiansen, Jens Meldgaard Bruun, Jan Alsner, Deirdre Cronin-Fenton, Signe Borgquist
Breast Cancer Research.2025;[Epub] CrossRef
An immunohistochemical characterization of basal cell carcinoma in patients below 40 years of age
Vincent Waller, Myriam Boeschen, Thomas Lingscheidt, Mathias Stiller, Lena Eickenscheidt, Thomas Wilhelm, Sonja Grunewald, Mirjana Ziemer, Jan‐Christoph Simon, Hendrik Bläker, Maximilian von Laffert
JDDG: Journal der Deutschen Dermatologischen Gesellschaft.2025; 23(11): 1414. CrossRef
Clinical Relationship Between Serum ApoB, HER2, and Myocardial Ischemia Risk in Breast Cancer Patients
Yeyan Lei, Dongmei Li, Shuang Bai, Xing Zeng, Rongyuan Yang, Qing Liu
Cancer Reports.2025;[Epub] CrossRef
Dual-targeting and steric hindrance resolution in HER2 IHC: a novel approach to improve diagnostic sensitivity
Li Luo, Xi Zhang, Linqiong Chen, Zhuohan Chen, Yuchen Wang, Kaihao Huang, Xiaoyun Lin, Hongxiang Zhu, Wangqi Du
BMC Cancer.2025;[Epub] CrossRef
Time‐Dependent Diffusion MRI‐Based Microstructural Mapping for Characterizing HER2‐Zero, ‐Low, ‐Ultra‐Low, and ‐Positive Breast Cancer
Xiaoxia Wang, Yao Huang, Ying Cao, Huifang Chen, Xueqin Gong, Xiaosong Lan, Jiuquan Zhang, Zhaoxiang Ye
Journal of Magnetic Resonance Imaging.2025; 62(6): 1754. CrossRef
Digital pathology enabling lean management of HER2/neu testing in breast Cancer
Aishwarya Sharma, Prarthna Shah, Manali Ranade, Trupti Pai, Ayushi Sahay, Asawari Patil, Tanuja Shet, Heena Gupta, Devika Chauhan, Puneet Somal, Sankalp Sancheti, Sangeeta Desai
Journal of Pathology Informatics.2025; 19: 100515. CrossRef
Enhancing HER2-low breast cancer detection with quantitative transcriptomics
Maria-Anna Misiakou, Maj-Britt Jensen, Maj-Lis Talman, Bent Ejlertsen, Maria Rossing
npj Breast Cancer.2025;[Epub] CrossRef
Caracterización inmunohistoquímica del cáncer de mama correlacionado con histopatología,estudio realizado en un hospital de Ecuador
María Fernanda Calderón León, Diego Mauricio Cabrera Moyano, Jorge Daniel Cárdenas Rodríguez, Paula Andrea Vásquez Jaramillo, Andrea Alexandra Saltos Román, Maryoli González Sánchez
Journal of the Selva Andina Research Society.2025; 16(2): 116. CrossRef
Relationship of vitamin D receptor expression with hormone receptors and other clinicopathological features in primary breast carcinomas: A retrospective cross-sectional study
Yaşar Ünlü, Ethem Ömeroğlu, Abdülhalim Serden Ay, Meryem İlkay Eren Karanis, Kilinç Ayşe Nur Uğur, Esra Yilmaz
Medicine.2025; 104(35): e44222. CrossRef
Improving HER2 Diagnostics with Digital Real‐Time PCR for Ultrafast, Precise Prediction of Anti‐HER2 Therapy Response in Patients with Breast Cancer
Hee‐Joo Choi, Soo Young Park, Minsik Song, Jinhyuk Chang, YoonSik Kim, Hosub Park, Chihwan David Cha, Sohyeon Yang, Nam Hun Heo, Min Ji Song, Da Sol Kim, Hayeon Kim, Minuk Kim, Jae Eun Park, Yesung Lee, EunChae Ji, Heekyoung Chung, Ilecheon Jeong, Mineui
Small Methods.2025;[Epub] CrossRef
Unveiling Metabolic Signatures as Potential Biomarkers in Common Cancers: Insights from Lung, Breast, Colorectal, Liver, and Gastric Tumours
Kha Wai Hon, Rakesh Naidu
Biomolecules.2025; 15(10): 1376. CrossRef
Validation of ancillary procedures on formalin liquid fixed aspiration cytologic samples: from minimum to maximum
Orsolya Rideg, Tímea Dergez, Arnold Tóth, Tamás Tornóczky, Gábor Pavlovics, Endre Kálmán
American Journal of Clinical Pathology.2025; 164(6): 924. CrossRef
Challenges & recommendations for identification of human epidermal growth factor receptor -2 (HER2)-low metastatic breast cancer in India: Expert opinion statement
Neeraj Arora, Jyoti Bajpai, Amanjit Bal, Atul Batra, Anurag Gupta, Deepak Kumar Mishra, Geetashree Mukherjee, Trupti Pai, Mayur Parihar, Geeta V. Patil Okaly, Shilpa Prabhudesai, Milap Shah, Somashekhar S.P.
The Indian Journal of Medical Research.2025; 162: 279. CrossRef
Eine immunhistologische Charakterisierung des Basalzellkarzinoms bei Patienten unter 40 Jahren
Vincent Waller, Myriam Boeschen, Thomas Lingscheidt, Mathias Stiller, Lena Eickenscheidt, Thomas Wilhelm, Sonja Grunewald, Mirjana Ziemer, Jan‐Christoph Simon, Hendrik Bläker, Maximilian von Laffert
JDDG: Journal der Deutschen Dermatologischen Gesellschaft.2025; 23(11): 1414. CrossRef
Comparison of Immunohistochemical 2 (+) HER2 Gene Status with SISH in Invasive Breast Carcinoma
Alper Sayiner, Hatice Karaman, Fatma Şenel, Arzu Tasdemir, Merve Doğan, İpek Özer
Sakarya Medical Journal.2025; 15(4): 338. CrossRef
Concurrent genomic assessment of circulating tumour cells and ctDNA to guide therapy in metastatic breast cancer
Rebecca C. Allsopp, Karen Page, Evie Wren, Georgios Nteliopoulos, Kelly L. T. Gleason, Gurdeep Matharu Lall, Shradha Bhagani, Emmanuel Acheampong, Marc K. Wadsley, Raoul Charles Coombes, Jacqueline A. Shaw
BMC Cancer.2025;[Epub] CrossRef
Management Strategies and Outcomes in HR+/HER2− Metastatic Breast Cancer Receiving CDK4/6 Inhibitors and Subsequent Therapies
Katarzyna Pogoda, Hubert Pawlik, Anna Balata, Magdalena Czopowicz, Agata Bak, Iwona Twardowska, Malgorzata Meluch, Maria Wojda, Agnieszka Mlodzinska, Ewa Szombara, Renata Sienkiewicz, Aleksandra Konieczna, Elzbieta Brewczynska, Izabela Lemanska, Anna Majs
Breast Cancer: Targets and Therapy.2025; Volume 17: 1307. CrossRef
Identification of novel chemical scaffolds against kinase domain of cancer causing human epidermal growth factor receptor 2: a systemic chemoinformatic approach
Faris Alrumaihi
Journal of Biomolecular Structure and Dynamics.2024; 42(12): 6269. CrossRef
Standardized pathology report for HER2 testing in compliance with 2023 ASCO/CAP updates and 2023 ESMO consensus statements on HER2-low breast cancer
Mariia Ivanova, Francesca Maria Porta, Marianna D’Ercole, Carlo Pescia, Elham Sajjadi, Giulia Cursano, Elisa De Camilli, Oriana Pala, Giovanni Mazzarol, Konstantinos Venetis, Elena Guerini-Rocco, Giuseppe Curigliano, Giuseppe Viale, Nicola Fusco
Virchows Archiv.2024; 484(1): 3. CrossRef
Analytical Performance Evaluation of a 523-Gene Circulating Tumor DNA Assay for Next-Generation Sequencing–Based Comprehensive Tumor Profiling in Liquid Biopsy Samples
Johannes Harter, Eleonora Buth, Janina Johaenning, Florian Battke, Maria Kopp, Henning Zelba, Martin Schulze, Jiri Koedding, Saskia Biskup
The Journal of Molecular Diagnostics.2024; 26(1): 61. CrossRef
Are There More HER2 FISH in the Sea? An Institution’s Experience in Identifying HER2 Positivity Using Fluorescent In Situ Hybridization in Patients with HER2 Negative Immunohistochemistry
Camille Suydam, Fairouz Chibane, Nicole Brown, Madeleine Schlafly, Alicia H. Arnold, Intisar Ghleilib, Melissa Easley, Joseph White
Annals of Surgical Oncology.2024; 31(1): 376. CrossRef
HER2 copy number determination in breast cancer using the highly sensitive droplet digital PCR method
Beate Alinger-Scharinger, Cornelia Kronberger, Georg Hutarew, Wolfgang Hitzl, Roland Reitsamer, Klaassen-Federspiel Frederike, Martina Hager, Thorsten Fischer, Karl Sotlar, Heidi Jaksch-Bogensperger
Virchows Archiv.2024; 485(1): 53. CrossRef
Impact of HER2-low status for patients with early-stage breast cancer and non-pCR after neoadjuvant chemotherapy: a National Cancer Database Analysis
Huiyue Li, Jennifer K. Plichta, Kan Li, Yizi Jin, Samantha M. Thomas, Fei Ma, Li Tang, Qingyi Wei, You-Wen He, Qichen Chen, Yuanyuan Guo, Yueping Liu, Jian Zhang, Sheng Luo
Breast Cancer Research and Treatment.2024; 204(1): 89. CrossRef
Qualification of a multiplexed tissue imaging assay and detection of novel patterns of HER2 heterogeneity in breast cancer
Jennifer L. Guerriero, Jia-Ren Lin, Ricardo G. Pastorello, Ziming Du, Yu-An Chen, Madeline G. Townsend, Kenichi Shimada, Melissa E. Hughes, Siyang Ren, Nabihah Tayob, Kelly Zheng, Shaolin Mei, Alyssa Patterson, Krishan L. Taneja, Otto Metzger, Sara M. Tol
npj Breast Cancer.2024;[Epub] CrossRef
Clinical Utility and Benefits of Comprehensive Genomic Profiling in Cancer
Melissa Yuwono Tjota, Jeremy P Segal, Peng Wang
The Journal of Applied Laboratory Medicine.2024; 9(1): 76. CrossRef
High contrast breast cancer biomarker semi-quantification and immunohistochemistry imaging using upconverting nanoparticles
Sanathana Konugolu Venkata Sekar, Hui Ma, Katarzyna Komolibus, Gokhan Dumlupinar, Matthias J. Mickert, Krzysztof Krawczyk, Stefan Andersson-Engels
Biomedical Optics Express.2024; 15(2): 900. CrossRef
HER2-low breast cancer and response to neoadjuvant chemotherapy: a population-based cohort study
Ximena Baez-Navarro, Mieke R. van Bockstal, Agnes Jager, Carolien H.M. van Deurzen
Pathology.2024; 56(3): 334. CrossRef
Fast-tracking drug development with biomarkers and companion diagnostics
Noreen McBrearty, Devika Bahal, Suso Platero
Journal of Cancer Metastasis and Treatment.2024;[Epub] CrossRef
Emerging Landscape of Targeted Therapy of Breast Cancers With Low Human Epidermal Growth Factor Receptor 2 Protein Expression
Gary Tozbikian, Savitri Krishnamurthy, Marilyn M. Bui, Michael Feldman, David G. Hicks, Shabnam Jaffer, Thaer Khoury, Shi Wei, Hannah Wen, Paula Pohlmann
Archives of Pathology & Laboratory Medicine.2024; 148(2): 242. CrossRef
Treatment Patterns and Health Outcomes among Patients with HER2 IHC0/-Low Metastatic or Recurrent Breast Cancer
Eliya Farah, Chantelle Carbonell, Devon J. Boyne, Darren R. Brenner, Jan-Willem Henning, Daniel Moldaver, Simran Shokar, Winson Y. Cheung
Cancers.2024; 16(3): 518. CrossRef
Clinical Internal Dosimetry and Biodistribution of 177Lu-DOTA-Trastuzumab in HER2-Positive Metastatic and Locally Advanced Breast Carcinoma
Yoga S. Narwadkar, Rahul V. Parghane, Sudeep Sahu, Sangita Lad, Kamal Deep, Gaurav Wanage, Tejal Suralkar, Sharmila Banerjee, Sudeep Gupta, Sandip Basu, Rajendra A. Badwe
Clinical Nuclear Medicine.2024; 49(4): e149. CrossRef
Molecular Classifications in Gastric Cancer: A Call for Interdisciplinary Collaboration
Cristina Díaz del Arco, María Jesús Fernández Aceñero, Luis Ortega Medina
International Journal of Molecular Sciences.2024; 25(5): 2649. CrossRef
The combined immunohistochemical expression of AMBRA1 and SQSTM1 identifies patients with poorly differentiated cutaneous squamous cell carcinoma at risk of metastasis: A proof of concept study
Michael H. Alexander, William J. Cousins, Tom Ewen, Andrew P. South, Penny Lovat, Niki Stefanos
Journal of Cutaneous Pathology.2024; 51(6): 450. CrossRef
Concordance between pathologists and between specimen types in detection of HER2-low breast carcinoma by immunohistochemistry
Jing Wang, Esther Yoon, Savitri Krishnamurthy
Annals of Diagnostic Pathology.2024; 70: 152288. CrossRef
Detection of HER2 expression using 99mTc-NM-02 nanobody in patients with breast cancer: a non-randomized, non-blinded clinical trial
Lingzhou Zhao, Yan Xing, Changcun Liu, Shaofei Ma, Wenhua Huang, Zhen Cheng, Jinhua Zhao
Breast Cancer Research.2024;[Epub] CrossRef
Pyrotinib and Trastuzumab Plus Chemotherapy Serve as an Acceptable Neoadjuvant Regimen Exhibiting Good Efficacy and Tolerance in HER2-Positive Breast Cancer Patients
Yibo Chen, Tianyi Zhang, Rui Zhang, Xuchen Cao
Cancer Biotherapy and Radiopharmaceuticals.2024; 39(6): 435. CrossRef
Clinicopathological and prognostic significance of VEGF, PDGF-B, and HER2/neu expression in gallbladder cancer
Pooja Shukla, Kumudesh Mishra, Ratnakar Shukla, Ruchira Vishwakarma, Niraj Kumari, Narendra Krishnani, Anu Behari, Vinay K. Kapoor
Journal of Cancer Research and Therapeutics.2024; 20(1): 349. CrossRef
Open questions, current challenges, and future perspectives in targeting human epidermal growth factor receptor 2-low breast cancer
G. Curigliano, R. Dent, H. Earle, S. Modi, P. Tarantino, G. Viale, S.M. Tolaney
ESMO Open.2024; 9(4): 102989. CrossRef
Concordance of HER2 status between core needle biopsy and surgical resection specimens of breast cancer: an analysis focusing on the HER2-low status
Sei Na, Milim Kim, Yujun Park, Hyun Jung Kwon, Hee-Chul Shin, Eun-Kyu Kim, Mijung Jang, Sun Mi Kim, So Yeon Park
Breast Cancer.2024; 31(4): 705. CrossRef
Impact of Neoadjuvant Chemotherapy (NAC) on Biomarker Expression in Breast Cancer
Suji Lee, Jee Yeon Kim, So Jeong Lee, Chung Su Hwang, Hyun Jung Lee, Kyung Bin Kim, Jung Hee Lee, Dong Hoon Shin, Kyung Un Choi, Chang Hun Lee, Gi Yeong Huh, Ahrong Kim
Medicina.2024; 60(5): 737. CrossRef
Clinical Use of Molecular Biomarkers in Canine and Feline Oncology: Current and Future
Heike Aupperle-Lellbach, Alexandra Kehl, Simone de Brot, Louise van der Weyden
Veterinary Sciences.2024; 11(5): 199. CrossRef
Clinical Validation of Artificial Intelligence–Powered PD-L1 Tumor Proportion Score Interpretation for Immune Checkpoint Inhibitor Response Prediction in Non–Small Cell Lung Cancer
Hyojin Kim, Seokhwi Kim, Sangjoon Choi, Changhee Park, Seonwook Park, Sergio Pereira, Minuk Ma, Donggeun Yoo, Kyunghyun Paeng, Wonkyung Jung, Sehhoon Park, Chan-Young Ock, Se-Hoon Lee, Yoon-La Choi, Jin-Haeng Chung
JCO Precision Oncology.2024;[Epub] CrossRef
Mesenchymal-epithelial transition factor amplification correlates with adverse pathological features and poor clinical outcome in colorectal cancer
Qiu-Xiao Yu, Ping-Ying Fu, Chi Zhang, Li Li, Wen-Ting Huang
World Journal of Gastrointestinal Surgery.2024; 16(5): 1395. CrossRef
Lipid nanoparticles-based RNA therapies for breast cancer treatment
Luigia Serpico, Yuewen Zhu, Renata Faria Maia, Sumedha Sumedha, Mohammad-Ali Shahbazi, Hélder A. Santos
Drug Delivery and Translational Research.2024; 14(10): 2823. CrossRef
Human epidermal growth factor receptor 2 (HER2) status in breast cancer: practice points and challenges
Natthawadee Laokulrath, Mihir Gudi, Syed Ahmed Salahuddin, Angela Phek Yoon Chong, Cristine Ding, Jabed Iqbal, Wei Qiang Leow, Benjamin Yongcheng Tan, Gary Tse, Emad Rakha, Puay Hoon Tan
Histopathology.2024; 85(3): 371. CrossRef
Comprehensive Immunohistochemical Analysis of Epithelial–Mesenchymal Transition Biomarkers in the Invasive Micropapillary Cancer of the Breast
Ozden Oz, Funda Alkan Tasli, Resmiye Irmak Yuzuguldu, Baha Zengel, Demet Kocatepe Cavdar, Merih Guray Durak, Raika Durusoy, Pranshu Sahgal
International Journal of Breast Cancer.2024;[Epub] CrossRef
Advancing HER2-low breast cancer management: enhancing diagnosis and treatment strategies
Simona Borstnar, Ivana Bozovic-Spasojevic, Ana Cvetanovic, Natalija Dedic Plavetic, Assia Konsoulova, Erika Matos, Lazar Popovic, Savelina Popovska, Snjezana Tomic, Eduard Vrdoljak
Radiology and Oncology.2024; 58(2): 258. CrossRef
Peer‐to‐peer validation of Ki‐67 scoring in a pathology quality circle as a tool to assess interobserver variability: are we better than we thought?
Marit Bernhardt, Leonie Weinhold, Christine Sanders, Oliver Hommerding, Jan‐Frederic Lau, Marieta Toma, Verena Tischler, Matthias Schmid, Tomasz Zienkiewicz, Ralf Hildenbrand, Peter Gerlach, Hui Zhou, Martin Braun, Gunnar Müller, Erich Sieber, Christian M
APMIS.2024; 132(10): 718. CrossRef
Immunohistochemical Expression of Cyclin D1 and p16 in Invasive Breast Carcinoma and Its Association with Clinicopathological Parameters
Shaivy Malik, Shakthivel V., Sana Ahuja, Charanjeet Ahluwalia
Indian Journal of Surgical Oncology.2024; 15(4): 864. CrossRef
Novel engineered HER2 specific recombinant protein nanocages for targeted drug delivery
Javad Kheshti, Mohammad Ahmadyousefi, Meysam Soleimani
Molecular Biology Reports.2024;[Epub] CrossRef
Circulating C-reactive protein levels as a prognostic biomarker in breast cancer across body mass index groups
J. B. Holm, E. Baggesen, D. Cronin-Fenton, J. Frystyk, J. M. Bruun, P. Christiansen, S. Borgquist
Scientific Reports.2024;[Epub] CrossRef
Standardized molecular pathology workflow for ctDNA-based ESR1 testing in HR+/HER2- metastatic breast cancer
Elena Guerini-Rocco, Konstantinos Venetis, Giulia Cursano, Eltjona Mane, Chiara Frascarelli, Francesco Pepe, Mariachiara Negrelli, Edoardo Olmeda, Davide Vacirca, Alberto Ranghiero, Dario Trapani, Carmen Criscitiello, Giuseppe Curigliano, Christian Rolfo,
Critical Reviews in Oncology/Hematology.2024; 201: 104427. CrossRef
The differences between pure and mixed invasive micropapillary breast cancer: the epithelial–mesenchymal transition molecules and prognosis
Ozden Oz, Resmiye Irmak Yuzuguldu, Ayse Yazici, Demet Kocatepe Cavdar, Cengiz Yilmaz, Mucteba Ozturk, Hilal Duzel, Duygu Gurel
Breast Cancer Research and Treatment.2024; 208(1): 41. CrossRef
Best practices for achieving consensus in HER2‐low expression in breast cancer: current perspectives from practising pathologists
Gary Tozbikian, Marilyn M. Bui, David G Hicks, Shabnam Jaffer, Thaer Khoury, Hannah Y Wen, Savitri Krishnamurthy, Shi Wei
Histopathology.2024; 85(3): 489. CrossRef
Consensus Guidelines on Human Epidermal Growth Factor Receptor 2 (HER2)-Low Testing in Breast Cancer in Malaysia
Pathmanathan Rajadurai, Sarala Ravindran, Bang Rom Lee, Suria Hayati Md Pauzi, Seow Fan Chiew, Kean Hooi Teoh, Navarasi S. Raja Gopal, Mastura Md Yusof, Cheng Har Yip
Cancers.2024; 16(13): 2325. CrossRef
Revolutionizing Pathology with Artificial Intelligence: Innovations in Immunohistochemistry
Diana Gina Poalelungi, Anca Iulia Neagu, Ana Fulga, Marius Neagu, Dana Tutunaru, Aurel Nechita, Iuliu Fulga
Journal of Personalized Medicine.2024; 14(7): 693. CrossRef
Interobserver Variability in HER‐2 Immunostaining Interpretation of Metastatic HER2 Low Breast Cancers in Cytology Specimens
Niyati Desai, Courtney F. Connelly, Simon Sung, Adela Cimic, Swikrity U. Baskota
Diagnostic Cytopathology.2024; 52(12): 722. CrossRef
Weakly-supervised deep learning models enable HER2-low prediction from H &E stained slides
Renan Valieris, Luan Martins, Alexandre Defelicibus, Adriana Passos Bueno, Cynthia Aparecida Bueno de Toledo Osorio, Dirce Carraro, Emmanuel Dias-Neto, Rafael A. Rosales, Jose Marcio Barros de Figueiredo, Israel Tojal da Silva
Breast Cancer Research.2024;[Epub] CrossRef
Understanding the spectrum of HER2 status in breast cancer: From HER2-positive to ultra-low HER2
Sana Ahuja, Adil Aziz Khan, Sufian Zaheer
Pathology - Research and Practice.2024; 262: 155550. CrossRef
Systematic review of added immunotherapy in traditional treatment for HER2 positive breast cancer patients
Rohan Choudhari
Innovative Practice in Breast Health.2024; 3-4: 100013. CrossRef
Detecting early-stage breast cancer with GATA3-positive circulating tumor cells
Chun-Hsin Hsieh, Ya-Herng Chang, Pei-Ying Ling, Ying-Tai Jin, Pei-Hsuan Lo, Hei-Jen Jou
Taiwanese Journal of Obstetrics and Gynecology.2024; 63(5): 745. CrossRef
First-in-human study of DP303c, a HER2-targeted antibody-drug conjugate in patients with HER2 positive solid tumors
Jian Zhang, Yiqun Du, Yanchun Meng, Xiaojun Liu, Yuxin Mu, Yunpeng Liu, Yehui Shi, Jufeng Wang, Aimin Zang, Shanzhi Gu, Tianshu Liu, Huan Zhou, Hongqian Guo, Silong Xiang, Xialu Zhang, Suqiong Wu, Huanhuan Qi, Mengke Li, Xichun Hu
npj Precision Oncology.2024;[Epub] CrossRef
Targeting CD276 for T cell-based immunotherapy of breast cancer
Ilona Hagelstein, Laura Wessling, Alexander Rochwarger, Latifa Zekri, Boris Klimovich, Christian M. Tegeler, Gundram Jung, Christian M. Schürch, Helmut R. Salih, Martina S. Lutz
Journal of Translational Medicine.2024;[Epub] CrossRef
Correlation of Androgen Receptor Expression With Ki67 Proliferative Index and Other Clinicopathological Characteristics in Invasive Mammary Carcinomas
D Keerthana Devi, V Pavithra, Leena D Joseph, Chithra Bhanu Challa
Cureus.2024;[Epub] CrossRef
CD81-guided heterologous EVs present heterogeneous interactions with breast cancer cells
Elena Gurrieri, Giulia Carradori, Michela Roccuzzo, Michael Pancher, Daniele Peroni, Romina Belli, Caterina Trevisan, Michela Notarangelo, Wen-Qiu Huang, Agata S. A. Carreira, Alessandro Quattrone, Guido Jenster, Timo L. M. Ten Hagen, Vito Giuseppe D’Agos
Journal of Biomedical Science.2024;[Epub] CrossRef
Deciphering HER2-low breast cancer (BC): insights from real-world data in early stage breast cancer
Anna Pous, Adrià Bernat-Peguera, Assumpció López-Paradís, Beatriz Cirauqui, Vanesa Quiroga, Iris Teruel, Eudald Felip, Angelica Ferrando-Díez, Milana Bergamino, Laia Boronat, Margarita Romeo, Gemma Soler, Christian Mariño, Paula Rodríguez-Martínez, Laura
Therapeutic Advances in Medical Oncology.2024;[Epub] CrossRef
Liquid biopsy-based technologies: a promising tool for biomarker identification in her2-low breast cancer patients for improved therapeutic outcomes
Aldo D’Alessandro, Anca Florentina Deaconu, Sandro Mandolesi, Federico Pio Fabrizio, Massimo Lombardi, Giovanna Liguori, Giovanni Pepe, Nicola Marino, Aureliano Stingi, Alessandro D’Alessandro, Antonio Giordano
Journal of Cancer Metastasis and Treatment.2024;[Epub] CrossRef
SPP1 mRNA Expression Is Associated with M2 Macrophage Infiltration and Poor Prognosis in Triple-Negative Breast Cancer
Yu-Chia Chen, Chia-Ching Chen, Rong-Fu Chen, Hsin-Hung Chen, Po-Ming Chen
Current Issues in Molecular Biology.2024; 46(12): 13499. CrossRef
MicroRNAs and their role in breast cancer metabolism (Review)
Wen Lee, Bann Yeo, Rozi Mahmud, Geok Tan, Mohamed Wahid, Yoke Cheah
International Journal of Oncology.2024;[Epub] CrossRef
CDH1 methylation and expression of E-cadherin and other markers in breast cancer
Luiz Fernando de Queiroz, Marcelo Soares da Mota e Silva, Fernando Colonna Rosman, Siane Lopes Bittencourt Rosas, Heitor Siffert Pereira de Souza, Maria da Glória da Costa Carvalho
Mastology.2024;[Epub] CrossRef
Surgical Management of the Axilla in HR+/HER2– Breast Cancer in the Z1071 Era: A Propensity Score-Matched Analysis of the National Cancer Database
Vayda R. Barker, Samer A. Naffouje, Melissa A. Mallory, Susan A. Hoover, Christine Laronga
Annals of Surgical Oncology.2023; 30(13): 8371. CrossRef
Noninvasive identification of HER2-low-positive status by MRI-based deep learning radiomics predicts the disease-free survival of patients with breast cancer
Yuan Guo, Xiaotong Xie, Wenjie Tang, Siyi Chen, Mingyu Wang, Yaheng Fan, Chuxuan Lin, Wenke Hu, Jing Yang, Jialin Xiang, Kuiming Jiang, Xinhua Wei, Bingsheng Huang, Xinqing Jiang
European Radiology.2023; 34(2): 899. CrossRef
Systemic investigation of inetetamab in combination with small molecules to treat HER2-overexpressing breast and gastric cancers
Lan Deng, Le Zhao, Lifen Liu, Haomin Huang
Open Life Sciences.2023;[Epub] CrossRef
HER2-low expression in patients with advanced or metastatic solid tumors
B. Uzunparmak, C. Haymaker, G. Raso, S. Masciari, L. Wang, H. Lin, A. Gorur, B. Kirby, A.-M. Cimo, A. Kennon, Q. Ding, G. Urschel, Y. Yuan, G. Feng, Y. Rizvi, A. Hussain, C. Zhu, P. Kim, G. Abbadessa, V. Subbiah, T.A. Yap, J. Rodon, S.A. Piha-Paul, F. Mer
Annals of Oncology.2023; 34(11): 1035. CrossRef
Data on 2D culture characterisation of potential markers in human HER2-positive breast cancer cell lines
Son H. Pham, Lyn R. Griffiths, Rachel K. Okolicsanyi, Larisa M. Haupt
Data in Brief.2023; 46: 108880. CrossRef
Determining HER2 Status by Artificial Intelligence: An Investigation of Primary, Metastatic, and HER2 Low Breast Tumors
Christiane Palm, Catherine E. Connolly, Regina Masser, Barbara Padberg Sgier, Eva Karamitopoulou, Quentin Simon, Beata Bode, Marianne Tinguely
Diagnostics.2023; 13(1): 168. CrossRef
Gene amplification mutations originate prior to selective stress in Acinetobacter baylyi
Jennifer A Herrmann, Agata Koprowska, Tesa J Winters, Nancy Villanueva, Victoria D Nikityuk, Feini Pek, Elizabeth M Reis, Constancia Z Dominguez, Daniel Davis, Eric McPherson, Staci R Rocco, Cynthia Recendez, Shyla M Difuntorum, Kelly Faeth, Mario D Lopez
G3.2023;[Epub] CrossRef
Flow Rate-Independent Multiscale Liquid Biopsy for Precision Oncology
Jie Wang, Robert Dallmann, Renquan Lu, Jing Yan, Jérôme Charmet
ACS Sensors.2023; 8(3): 1200. CrossRef
Single-cell HER2 quantification via instant signal amplification in microdroplets
Xiaoxian Liu, Yifan Zhu, Caoxin Li, Yanyun Fang, Jinna Chen, Fei Xu, Yanqing Lu, Perry Ping Shum, Ying Liu, Guanghui Wang
Analytica Chimica Acta.2023; 1251: 340976. CrossRef
Molecular imaging of HER2 receptor: Targeting HER2 for imaging and therapy in nuclear medicine
Daniela Miladinova
Frontiers in Molecular Biosciences.2023;[Epub] CrossRef
CORRELATION BETWEEN DIFFERENT CLINICOPATHOLOGICAL PARAMETERS AND MOLECULAR SUBTYPES OF FEMALE BREAST CARCINOMA IN SOUTH REGION OF IRAQ
Yassir Alaa Muhammed Hassan Shubbar
Wiadomości Lekarskie.2023; 76(1): 97. CrossRef
Pathological identification of HER2-low breast cancer: Tips, tricks, and troubleshooting for the optimal test
Elham Sajjadi, Elena Guerini-Rocco, Elisa De Camilli, Oriana Pala, Giovanni Mazzarol, Konstantinos Venetis, Mariia Ivanova, Nicola Fusco
Frontiers in Molecular Biosciences.2023;[Epub] CrossRef
Protective Effect of HER2 Gene Polymorphism rs24537331 in the Outcome of Canine Mammary Tumors
Ana Canadas-Sousa, Marta Santos, Patrícia Dias-Pereira
Animals.2023; 13(8): 1384. CrossRef
Can Patients with HER2-Low Breast Cancer Benefit from Anti-HER2 Therapies? A Review
Jin Wang, Dongying Liao, Xuemin Zhang, Changhong Miao, Kuang Chen
Breast Cancer: Targets and Therapy.2023; Volume 15: 281. CrossRef
HER2 Low Breast Cancer: A New Subtype or a Trojan for Cytotoxic Drug Delivery?
Marina Popović, Tajana Silovski, Marija Križić, Natalija Dedić Plavetić
International Journal of Molecular Sciences.2023; 24(9): 8206. CrossRef
HER2-Low Breast Cancer—Diagnostic Challenges and Opportunities for Insights from Ongoing Studies: A Podcast
Aditya Bardia, Giuseppe Viale
Targeted Oncology.2023; 18(3): 313. CrossRef
Histopathological and immunohistochemical analysis of predictive and prognostic markers in spontaneous canine mammary cancer
Vladimír Tancoš, Marcel Kovalik, Martin Levkut, Martina Bobrovská, Petra Kolenčíková, Ľubomír Straka, Zuzana Ševčíková, Ondřej Škor, Martina Antošová, Lukáš Plank, Keith L. Thoday
Acta Veterinaria Brno.2023; 92(2): 143. CrossRef
Dissecting sources of variability in patient response to targeted therapy: anti-HER2 therapies as a case study
Timothy Qi, Yanguang Cao
European Journal of Pharmaceutical Sciences.2023; 186: 106467. CrossRef
The Effect of HER2-Low Status on Pathological Complete Response and Survival in Triple-Negative Breast Cancer: A Systemic Review and Meta-Analysis
Yakup Ergun, Baran Akagunduz, Cengiz Karacin, Sema Turker, Gokhan Ucar
Clinical Breast Cancer.2023; 23(6): 567. CrossRef
Efficacy, toxicity and prognostic factors of pyrotinib‑involved neoadjuvant therapy in HER2‑positive breast cancer: A retrospective study
Hao Wang, Hailing Cao, Zhiyun Guo
Oncology Letters.2023;[Epub] CrossRef
Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer
Feng Ye, Saikat Dewanjee, Yuehua Li, Niraj Kumar Jha, Zhe-Sheng Chen, Ankush Kumar, Vishakha, Tapan Behl, Saurabh Kumar Jha, Hailin Tang
Molecular Cancer.2023;[Epub] CrossRef
Weakly supervised bilayer convolutional network in segmentation of HER2 related cells to guide HER2 targeted therapies
Ching-Wei Wang, Kun-Lin Lin, Hikam Muzakky, Yi-Jia Lin, Tai-Kuang Chao
Computerized Medical Imaging and Graphics.2023; 108: 102270. CrossRef
Immune Biomarkers in Triple-Negative Breast Cancer: Improving the Predictivity of Current Testing Methods
Francesca Maria Porta, Elham Sajjadi, Konstantinos Venetis, Chiara Frascarelli, Giulia Cursano, Elena Guerini-Rocco, Nicola Fusco, Mariia Ivanova
Journal of Personalized Medicine.2023; 13(7): 1176. CrossRef
HER2 Equivocal (Score = 2+) Breast Carcinoma Cases Identified by Immunohistochemistry at a South African Hospital. What is the Impact of Fluorescent In Situ Hybridization Testing?
Reena Dhansukh Mohanlal, Nikki Bouwer, Pascale Willem
Applied Immunohistochemistry & Molecular Morphology.2023; 31(8): 555. CrossRef
Discordance of HER2 Expression and/or Amplification on Repeat Testing
Timothy P. DiPeri, Kathleen Kong, Kaushik Varadarajan, Daniel D. Karp, Jaffer A. Ajani, Shubham Pant, Michael F. Press, Sarina A. Piha-Paul, Ecaterina E. Dumbrava, Funda Meric-Bernstam
Molecular Cancer Therapeutics.2023; 22(8): 976. CrossRef
Low and Ultra-Low HER2 in Human Breast Cancer: An Effort to Define New Neoplastic Subtypes
Mariausilia Franchina, Cristina Pizzimenti, Vincenzo Fiorentino, Maurizio Martini, Giuseppina Rosaria Rita Ricciardi, Nicola Silvestris, Antonio Ieni, Giovanni Tuccari
International Journal of Molecular Sciences.2023; 24(16): 12795. CrossRef
Genetic analysis of oligo-recurrence breast cancer: correlation with clinical outcomes
Kuikui Jiang, Danyang Zhou, Fei Xu, Wen Xia, Qiufan Zheng, Qianyi Lu, Rongzhen Luo, Ruoxi Hong, Shusen Wang
BMC Cancer.2023;[Epub] CrossRef
Single domain antibodies specific for HER2 dimerization domain effectively disrupts HER2 dimerization
Ahmad Najafi, Reza Valadan, Hossein Asgarian-Omran, Alireza Rafiei, Mohsen Tehrani
International Immunopharmacology.2023; 124: 110999. CrossRef
Récepteur du facteur de croissance épidermique HER2, tests utilisés pour rechercher son amplification dans le cancer du sein : principes et limites
Imane Eliahiai, Mohammed Eljiar, Sanae Chaib, Jinane KHarmoum, Mariame Chraïbi
Bulletin du Cancer.2023; 110(12): 1301. CrossRef
Integrated Molecular Characterization of HER2-Low Breast Cancer Using Next Generation Sequencing (NGS)
Jean-Louis Merlin, Marie Husson, Nassim Sahki, Pauline Gilson, Vincent Massard, Alexandre Harlé, Agnès Leroux
Biomedicines.2023; 11(12): 3164. CrossRef
GLUCOSE LEVELS OF PLEURAL EFFUSION FLUID AND HER2 STATUS IN PLEURAL-METASTATIC BREAST CANCER
Muhammad Dhanny Irawan, Desak Gede Agung Suprabawati, Heru Purwanto
Majalah Biomorfologi.2023; 33(2): 75. CrossRef
Design of a Ratiometric Plasmonic Biosensor for Herceptin Detection in HER2-Positive Breast Cancer
Neda Shahbazi, Rouholah Zare-Dorabei, Seyed Morteza Naghib
ACS Biomaterials Science & Engineering.2022; 8(2): 871. CrossRef
A highly sensitive nanobiosensor based on aptamer-conjugated graphene-decorated rhodium nanoparticles for detection of HER2-positive circulating tumor cells
Mahdi Sadeghi, Soheila Kashanian, Seyed Morteza Naghib, Esfandyar Askari, Fateme Haghiralsadat, Davood Tofighi
Nanotechnology Reviews.2022; 11(1): 793. CrossRef
Anti-HER2 therapy in metastatic breast cancer: many choices and future directions
Carrie S. Wynn, Shou-Ching Tang
Cancer and Metastasis Reviews.2022; 41(1): 193. CrossRef
Electroanalytical overview: screen-printed electrochemical sensing platforms for the detection of vital cardiac, cancer and inflammatory biomarkers
Robert D. Crapnell, Alejandro Garcia-Miranda Ferrari, Nina C. Dempsey, Craig E. Banks
Sensors & Diagnostics.2022; 1(3): 405. CrossRef
FTO genotype was associated with breast cancer in HER2 negative patients
Fateme Montazeri, Hossein Hatami, Soroor Fathi, Naeemeh Hasanpour Ardekanizadeh, Fatemeh Bourbour, Samira Rastgoo, Fatemeh Shafiee, Mohammad Esmail Akbari, Maryam Gholamalizadeh, Seyed Alireza Mosavi Jarrahi, Saeid Doaei
Clinical Nutrition ESPEN.2022; 49: 495. CrossRef
Breast Cancer Human Epidermal Growth Factor Receptor 2 mRNA Molecular Testing Compared to Immunohistochemistry with Correlation to Neoadjuvant Therapy Response
Mahmoud Behairy, Samia Mohamed Gabal, Mohamed Sherif Negm
Open Access Macedonian Journal of Medical Sciences.2022; 10(A): 352. CrossRef
Validity and utility of HER2/ERBB2 copy number variation assessed in liquid biopsies from breast cancer patients: A systematic review
Noortje Verschoor, Teoman Deger, Agnes Jager, Stefan Sleijfer, Saskia M. Wilting, John W.M. Martens
Cancer Treatment Reviews.2022; 106: 102384. CrossRef
RETRACTED: Longitude Variation of the microRNA-497/FGF-23 Axis during Treatment and Its Linkage with Neoadjuvant/Adjuvant Trastuzumab-Induced Cardiotoxicity in HER2-Positive Breast Cancer Patients
Hui Liu, Xiaoyan Hu, Lingyun Wang, Tao Du, Jing Feng, Ming Li, Lei Liu, Xiaofang Liu
Frontiers in Surgery.2022;[Epub] CrossRef
Use of Radionuclide-Based Imaging Methods in Breast Cancer
Betül Altunay, Agnieszka Morgenroth, Felix M. Mottaghy
Seminars in Nuclear Medicine.2022; 52(5): 561. CrossRef
Functional regulations between genetic alteration-driven genes and drug target genes acting as prognostic biomarkers in breast cancer
Li Wang, Lei Yu, Jian Shi, Feng Li, Caiyu Zhang, Haotian Xu, Xiangzhe Yin, Lixia Wang, Shihua Lin, Anastasiia Litvinova, Yanyan Ping, Shangwei Ning, Hongying Zhao
Scientific Reports.2022;[Epub] CrossRef
Human epidermal growth factor receptor-2 and endocrine resistance in hormone-dependent breast cancer
Anastasia Alataki, Mitch Dowsett
Endocrine-Related Cancer.2022; 29(8): R105. CrossRef
The Evolution of Targeted Radionuclide Diagnosis of HER2-Positive Breast Cancer
Olga D. Bragina, Sergei M. Deyev, Vladimir I. Chernov, Vladimir M. Tolmachev
Acta Naturae.2022; 14(2): 4. CrossRef
Deriving tumor purity from cancer next generation sequencing data: applications for quantitative ERBB2 (HER2) copy number analysis and germline inference of BRCA1 and BRCA2 mutations
Stephanie E. Siegmund, Danielle K. Manning, Phani K. Davineni, Fei Dong
Modern Pathology.2022; 35(10): 1458. CrossRef
Current challenges and unmet needs in treating patients with human epidermal growth factor receptor 2-positive advanced breast cancer
Matti Aapro, Fatima Cardoso, Giuseppe Curigliano, Alexandru Eniu, Joseph Gligorov, Nadia Harbeck, Andreas Mueller, Olivia Pagani, Shani Paluch-Shimon, Elzbieta Senkus, Beat Thürlimann, Khalil Zaman
The Breast.2022; 66: 145. CrossRef
[Retracted] Application of Fluorescence In Situ Hybridization Assisted by Fluorescence Microscope in Detection of Her2 Gene in Breast Cancer Patients
Fang Lu, Tingting Zhou, Yan Liu, Liying Song, Bin Zhang, Yuyan Li, Sorayouth Chumnanvej
Contrast Media & Molecular Imaging.2022;[Epub] CrossRef
High sensitivity label-free detection of HER2 using an Al–GaN/GaN high electron mobility transistor-based biosensor
Shivanshu Mishra, Pharyanshu Kachhawa, Amber Kumar Jain, Rajiv Ranjan Thakur, Nidhi Chaturvedi
Lab on a Chip.2022; 22(21): 4129. CrossRef
Indian Data on HER2 Fluorescence In Situ Hybridization in Invasive Breast Cancer with Immunohistochemically Equivocal Results As Per 2018 ASCO/CAP Guidelines
B. R. Nagarjun, Biren Parikh, Manaswi Nareshkumar Patel, Pina J. Trivedi, Dharmesh M. Patel
South Asian Journal of Cancer.2022; 11(04): 281. CrossRef
S‑phase fraction, lymph node status and disease staging as the main prognostic factors to differentiate between young and older patients with invasive breast carcinoma
António Pinto, João Matos, Teresa Pereira, Giovani Silva, Saudade André
Oncology Letters.2022;[Epub] CrossRef
Inferring tumor-specific cancer dependencies through integrating ex vivo drug response assays and drug-protein profiling
Alina Batzilla, Junyan Lu, Jarno Kivioja, Kerstin Putzker, Joe Lewis, Thorsten Zenz, Wolfgang Huber, James Gallo
PLOS Computational Biology.2022; 18(8): e1010438. CrossRef
Clinical possibilities of HER2-positive breast cancer diagnosis using alternative scaffold proteins
O. D. Bragina, V. I. Chernov, S. M. Deyev, V. M. Tolmachev
Bulletin of Siberian Medicine.2022; 21(3): 132. CrossRef
Molecular Pathology of Gastric Cancer
Moonsik Kim, An Na Seo
Journal of Gastric Cancer.2022; 22(4): 264. CrossRef
Loss of NECTIN1 triggers melanoma dissemination upon local IGF1 depletion
Julien Ablain, Amira Al Mahi, Harriet Rothschild, Meera Prasad, Sophie Aires, Song Yang, Maxim E. Dokukin, Shuyun Xu, Michelle Dang, Igor Sokolov, Christine G. Lian, Leonard I. Zon
Nature Genetics.2022; 54(12): 1839. CrossRef
Advanced diagnosis technologies for HER2 breast cancer markers
Mengxue Zhang
Highlights in Science, Engineering and Technology.2022; 14: 44. CrossRef
An Overview of Clinical Development of Agents for Metastatic or Advanced Breast Cancer Without ERBB2 Amplification (HER2-Low)
Aleix Prat, Aditya Bardia, Giuseppe Curigliano, M. Elizabeth H. Hammond, Sibylle Loibl, Sara M. Tolaney, Giuseppe Viale
JAMA Oncology.2022; 8(11): 1676. CrossRef
Development of T-cell engagers selective for cells co-expressing two antigens
Danielle M. Dicara, Sunil Bhakta, Mary Ann Go, James Ziai, Ron Firestein, Bill Forrest, Chen Gu, Steven R. Leong, Genee Lee, Shang-Fan Yu, Andrew G. Polson, Nicholas J. Agard
mAbs.2022;[Epub] CrossRef
The clinical significance of HER2 expression in DCIS
Ioanna Akrida, Francesk Mulita
Medical Oncology.2022;[Epub] CrossRef
Antibody-Drug Conjugates in Breast Cancer: Spotlight on HER2
Rachel Occhiogrosso Abelman, Arielle Medford, Laura Spring, Aditya Bardia
The Cancer Journal.2022; 28(6): 423. CrossRef
The Clinical Utility of Droplet Digital PCR for Profiling Circulating Tumor DNA in Breast Cancer Patients
Ugur Gezer, Abel J. Bronkhorst, Stefan Holdenrieder
Diagnostics.2022; 12(12): 3042. CrossRef
Lapatinib and lapatinib plus trastuzumab therapy versus trastuzumab therapy for HER2 positive breast cancer patients: an updated systematic review and meta-analysis
Ye Yuan, Xumei Liu, Yi Cai, Wenyuan Li
Systematic Reviews.2022;[Epub] CrossRef
Interactions dietary components with expression level of breast cancer-related genes
Fatemeh Bourbour, Azam Pourtaheri, Khadijeh Abbasi, Naeemeh Hasanpour Ardekanizadeh, Maryam Gholamalizadeh, Azadeh Hajipour, Sepideh Abdollahi, Seyedeh Elaheh Bagheri, Mina Ahmadzadeh, Saeid Doaei, Arezoo Haghighian
Egyptian Journal of Medical Human Genetics.2022;[Epub] CrossRef
HER2-directed antibodies, affibodies and nanobodies as drug-delivery vehicles in breast cancer with a specific focus on radioimmunotherapy and radioimmunoimaging
Betül Altunay, Agnieszka Morgenroth, Mohsen Beheshti, Andreas Vogg, Nicholas C. L. Wong, Hong Hoi Ting, Hans-Jürgen Biersack, Elmar Stickeler, Felix M. Mottaghy
European Journal of Nuclear Medicine and Molecular Imaging.2021; 48(5): 1371. CrossRef
Risk-based decision-making in the treatment of HER2-positive early breast cancer: Recommendations based on the current state of knowledge
Christian Jackisch, Patricia Cortazar, Charles E. Geyer, Luca Gianni, Joseph Gligorov, Zuzana Machackova, Edith A. Perez, Andreas Schneeweiss, Sara M. Tolaney, Michael Untch, Andrew Wardley, Martine Piccart
Cancer Treatment Reviews.2021; 99: 102229. CrossRef
Histologic Patterns of Cutaneous Metastases of Breast Carcinoma: A Clinicopathologic Study of 232 Cases
Shira Ronen, David Suster, Wei-Shen Chen, Natali Ronen, Sri Krishna C. Arudra, Celestine Trinidad, Doina Ivan, Victor G. Prieto, Saul Suster
The American Journal of Dermatopathology.2021; 43(6): 401. CrossRef
Standardized pathology report for breast cancer
Soo Youn Cho, So Yeon Park, Young Kyung Bae, Jee Yeon Kim, Eun Kyung Kim, Woo Gyeong Kim, Youngmee Kwon, Ahwon Lee, Hee Jin Lee, Ji Shin Lee, Jee Young Park, Gyungyub Gong, Hye Kyoung Yoon
Journal of Pathology and Translational Medicine.2021; 55(1): 1. CrossRef
The impact of oral contraceptive use on breast cancer risk: State of the art and future perspectives in the era of 4P medicine
R. Bonfiglio, M.L. Di Pietro
Seminars in Cancer Biology.2021; 72: 11. CrossRef
The Co-Expression of Melanoma-Antigen Family a Proteins and New York Esophageal Squamous Cell Carcinoma-1 in Breast Cancer: A Pilot Study
Yu-Xin Wang, Feng-Lian Li, Li-Xin Du, Jun-Fang Liu, Li-Gang Huo, Shu-Qing Li, Bin Tian
Cancer Management and Research.2021; Volume 13: 6123. CrossRef
Targeting HER2 protein in individual cells using ICP-MS detection and its potential as prognostic and predictive breast cancer biomarker
A. Fernández Asensio, M. Corte-Rodríguez, J. Bettmer, L.M. Sierra, M. Montes-Bayón, E. Blanco- González
Talanta.2021; 235: 122773. CrossRef
Development of a 99mTc-Labeled Single-Domain Antibody for SPECT/CT Assessment of HER2 Expression in Breast Cancer
Lingzhou Zhao, Changcun Liu, Yan Xing, Jin He, Jim O’Doherty, Wenhua Huang, Jinhua Zhao
Molecular Pharmaceutics.2021; 18(9): 3616. CrossRef
WITHDRAWN: Nouvelles stratégies thérapeutiques dans les cancers du sein HER2-surexprimé
Benoîte Mery, Philippe Toussaint, Pierre-Etienne Heudel, Armelle Dufresne, Mélodie Carbonnaux, Hélène Vanacker, Thomas Bachelot, Olivier Trédan
Bulletin du Cancer.2021;[Epub] CrossRef
Retrospective observational study of HER2 immunohistochemistry in borderline breast cancer patients undergoing neoadjuvant therapy, with an emphasis on Group 2 (HER2/CEP17 ratio ≥2.0, HER2 copy number <4.0 signals/cell) cases
Emad A. Rakha, Islam M. Miligy, Cecily M. Quinn, Elena Provenzano, Abeer M. Shaaban, Caterina Marchiò, Michael S. Toss, Grace Gallagy, Ciara Murray, Janice Walshe, Ayaka Katayama, Karim Eldib, Nahla Badr, Bruce Tanchel, Rebecca Millican-Slater, Colin Purd
British Journal of Cancer.2021; 124(11): 1836. CrossRef
Loss of HER2‐positivity following neoadjuvant targeted therapy for breast cancer is not associated with inferior oncologic outcomes
Catherine L. Wetzel, Thomas L. Sutton, Stuart Gardiner, Maryam Farinola, Nathalie Johnson, Jennifer R. Garreau
Journal of Surgical Oncology.2021; 124(8): 1224. CrossRef
Clinical and Genetic Predictive Models for the Prediction of Pathological Complete Response to Optimize the Effectiveness for Trastuzumab Based Chemotherapy
Lun Li, Min Chen, Shuyue Zheng, Hanlu Li, Weiru Chi, Bingqiu Xiu, Qi Zhang, Jianjing Hou, Jia Wang, Jiong Wu
Frontiers in Oncology.2021;[Epub] CrossRef
tRNA‐derived fragments: tRF‐Gly‐CCC‐046, tRF‐Tyr‐GTA‐010 and tRF‐Pro‐TGG‐001 as novel diagnostic biomarkers for breast cancer
Yue Zhang, Zhao Bi, Xiaohan Dong, Miao Yu, Kangyu Wang, Xingguo Song, Li Xie, Xianrang Song
Thoracic Cancer.2021; 12(17): 2314. CrossRef
Detection of secondary metastatic breast cancer by measurement of plasma CA 15.3
L. De Cock, J. Heylen, A. Wildiers, K. Punie, A. Smeets, C. Weltens, P. Neven, J. Billen, A. Laenen, H. Wildiers
ESMO Open.2021; 6(4): 100203. CrossRef
Standardized Pathology Report for Breast Cancer
Soo Youn Cho, So Yeon Park, Young Kyung Bae, Jee Yeon Kim, Eun Kyung Kim, Woo Gyeong Kim, Youngmee Kwon, Ahwon Lee, Hee Jin Lee, Ji Shin Lee, Jee Young Park, Gyungyub Gong, Hye Kyoung Yoon
Journal of Breast Cancer.2021; 24(1): 1. CrossRef
Circular RNA circ-ERBB2 promotes HER2-positive breast cancer progression and metastasis via sponging miR-136-5p and miR-198
Jin-xiu Zhong, Yun-yuan Kong, Rong-guang Luo, Guo-jin Xia, Wen-xing He, Xue-zhong Chen, Wei-wei Tan, Qing-jie Chen, Yu-yin Huang, Yan-xing Guan
Journal of Translational Medicine.2021;[Epub] CrossRef
Nouvelles stratégies thérapeutiques dans les cancers du sein HER2-surexprimé
Benoîte Mery, Philippe Toussaint, Pierre-Etienne Heudel, Armelle Dufresne, Mélodie Carbonnaux, Hélène Vanacker, Thomas Bachelot, Olivier Trédan
Bulletin du Cancer.2021; 108(11): 11S8. CrossRef
Association of Estrogen and Progesterone Receptors with Clinicopathological Prognostic Factors in Breast Cancer
Ali Abdul Hadi Abdul-Kareem, Qahtan A. Mahdi
Medical Journal of Babylon.2021; 18(2): 111. CrossRef
HER2 alterations in non-small-cell lung cancer – Druggable or undruggable?
Suresh Kumar Bondili, Ravindra Nandhana, Vanita Noronha, Swayamprabha Pawar, Nandini Menon, Omshree Shetty, Anuradha Chougule, Abhishek Mahajan, Rajiv Kumar, Vijay M. Patil, Amit Joshi, Kumar Prabhash
Cancer Research, Statistics, and Treatment.2021; 4(2): 374. CrossRef
UCNP-based Photoluminescent Nanomedicines for Targeted Imaging and Theranostics of Cancer
Evgenii L. Guryev, Anita S. Smyshlyaeva, Natalia Y. Shilyagina, Evgeniya A. Sokolova, Samah Shanwar, Alexey B. Kostyuk, Alexander V. Lyubeshkin, Alexey A. Schulga, Elena V. Konovalova, Quan Lin, Indrajit Roy, Irina V. Balalaeva, Sergey M. Deyev, Andrei V.
Molecules.2020; 25(18): 4302. CrossRef
Impact of the Updated Guidelines on Human Epidermal Growth Factor Receptor 2 (HER2) Testing in Breast Cancer
Min Chong Kim, Su Hwan Kang, Jung Eun Choi, Young Kyung Bae
Journal of Breast Cancer.2020; 23(5): 484. CrossRef

Original Articles

Metaplastic Squamous Carcinoma of the Breast: Clinicopathologic Analysis of 17 Cases.: Sun Ah Lee, Kyung Eun Lee, Byung In Moon, Woon Sup Han, Sun Hee Sung; Korean J Pathol. 2009;43(1):20-25.; DOI: https://doi.org/10.4132/KoreanJPathol.2009.43.1.20

4,936 View
48 Download
2 Crossref

Abstract PDF

BACKGROUND
Squamous cell carcinoma of the breast is very rare and it is considered to arise from metaplastic change of ductal carcinoma. Metaplastic squamous cell carcinoma (MSC) of the breast includes pure squamous cell carcinoma, metaplastic adenosquamous carcinoma and low grade adenosquamous carcinoma. Most of the cases of MSC of the breast were reported to have lymph node metastasis and this has a worse prognosis than that of conventional invasive ductal carcinoma.
METHODS
We collected 17 cases of MSC of the breast from 1,173 cases of breast cancer and analyzed the clinicopathological characteristics.
RESULTS
The age range was 31 to 69 years (mean age: 47.2). The mean tumor size was 3.6 cm. Twelve cases (70.6%) had a negative nodal status. The majority of the cases were of a high nuclear grade (grade III: 76.5%), and a high histologic grade (grade III: 88.2%). All the cases had no amplification of HER2, and they were negative for hormonal receptors, except for 2 cases with weak positivity. All the cases showed positivity for EGFR (3+: 14 cases, 1+: 3 cases). Clinical relapse was found in 3 patients on follow up and two of them expired due to lung and bone metastasis.
CONCLUSIONS
MSC is associated with high nuclear and histologic grades, a high EGFR expression and they are triple negative for ER, PR, and HER2. The EGFR immunopositivity of MSC suggests a basal-like subtype.

Citations

Citations to this article as recorded by

Eccrine ductal and acrosyringeal metaplasia in breast carcinomas: report of eight cases
Tibor Tot
Virchows Archiv.2019; 474(3): 383. CrossRef
Significance of Foxp3 Positive Regulatory T Cell and Tumor Infiltrating T Lymphocyte in Triple Negative Breast Cancer
Hanna Kang, Harin Cheong, Min Sun Cho, Heasoo Koo, Woon Sup Han, Kyung Eun Lee, Byung In Moon, Sun Hee Sung
The Korean Journal of Pathology.2011; 45(1): 53. CrossRef

The Expression of p53, c-erbB-2 and nm23 Proteins in Breast Cancer.: Kyo Young Lee, Yong Goo Kim, Young Shin Kim, Kyung Ja Han, Chang Suk Kang, Jean A Kim, Won Il Kim, Sang In Shim; Korean J Pathol. 1999;33(2):88-95.

1,842 View
10 Download

Abstract: Recently, p53, c-erbB-2 and nm23 proteins have been studied in breast cancer. The expression of p53 protein indicates the mutation of p53 gene known as a tumor supressor gene, and c-erbB-2 gene amplification has been considered an indicator of poor prognosis and nm23 a metastsis suppressor gene. In order to elucidate the roles and relations of these proteins in the develpoment, progression and metastasis in breast cancer, we studied 89 cases of invasive breast cancer and 32 cases of lymph node metastasis for the expression of p53, c-erbB-2 and nm23 proteins using an immunohistochemical method. The results were as follows: 1) The expression rates of p53, c-erbB-2, and nm23 proteins in breast cancer were 40.4%, 34.8% and 55.1%, respectively. Co-expression of p53 protein and c-erbB-2 protein was found in 20.2% of cases, showing the highest incidence in poorly differentiated type (40%). 2) p53 protein expression was increased in poorly differentiated type but was not statistically significant. On the other hand, the expression of nm23 protein was decreased in poorly differentiated type, which was statistically significant (p<0.05). 3) The correlation of p53 protein expression with c-erbB-2 protein expression was statistically significant (p<0.05) but that with nm23 protein was not. 4) In the cases with lymph node metastasis, discordant expression of p53, c-erbB-2 and nm23 proteins between primary tumor and the lymph node metastatic tumor was found in 9.4%, 3.1% and 18.8% of cases, respectively. The above results suggest that overexpression of p53 and c-erbB-2 proteins and downregulation of nm23 protein are associated with the tumor progression in the breast cancer.

The Relationship between PTEN Tumor Suppressor Gene and Vascular Endothelial Growth Factor-Mediated Angiogenesis in Breast Cancer.: Jean Kyung Park, Min Jung Jung, Bong Kwon Chun, Bang Hur; Korean J Pathol. 2004;38(2):100-105.

2,179 View
14 Download

Abstract PDF: BACKGROUND
PTEN is a novel tumor suppressor gene located at chromosome 10q23.3. Loss of PTEN function has been implicated in the progression of several types of cancer. Angiogenesis is a critical factor in tumor growth and metastasis. We investigated PTEN expression in invasive breast cancers and described its role in the regulation of angiogenesis related to vascular endothelial growth factor (VEGF).
METHODS
Forty-five, surgically resected, formalin-fixed and paraffin embedded breast cancer tissue samples were analyzed for PTEN and VEGF expressions by immunohistochemistry and for microvessel density (MVD) by CD34 immunostaining.
RESULTS
Loss of PTEN expression was found in 35.6% (16/45) of the breast cancer tissues, all of which showed positive VEGF expression. Among 29 cases with normal PTEN expression, 15 (51.7%) were VEGF positive. MVD was significantly higher in tumors with a loss of PTEN expression than in those with normal PTEN expression.
CONCLUSION
A loss of PTEN expression might increase the VEGF-related angiogenesis in breast cancer. There was no correlation between PTEN expression and clinicopathologic parameters. Detection of the loss of PTEN expression may serve as a useful biologic marker for progression in invasive breast cancer.

Expression of Anaphase Promoting Complex (APC) and APC Regulatory Proteins in Invasive Ductal Carcinoma Associated with Paget's Disease.: Kwang Hwa Park, Sang Yeop Yi, Woo Ick Yang, Yup Kang, Kwang Gil Lee; Korean J Pathol. 2004;38(5):319-323.

2,073 View
13 Download

Abstract PDF: BACKGROUND
Oncogene expression in Paget's disease of the breast is not well known. To characterize invasive ductal carcinoma associated with Paget's disease, we studied expression of anaphase promoting complex (APC) with its regulatory proteins.
METHODS
Immunohistochemical stainings were done with 10 cases of invasive ductal carcinoma associated with Paget's disease for APC, pituitary tumor transforming gene (PTTG), cyclin B1, p53, cyclin D1, and c-erbB-2. The expressions of these markers in Paget's disease were compared with those in the associated with carcinoma.
RESULTS
APC, PTTG, cyclin B1, and c-erbB-2 were positive in all of the cases with both Paget's disease and underlying carcinoma. p53 was expressed in Paget's disease of 6 cases (60%) and in carcinoma of 7 cases (70%). Cyclin D1 was positive in Paget's disease of 8 cases (80%) and in carcinoma of 9 cases (90%).
CONCLUSIONS
Breast carcinomas with Paget's disease seem to be distinguished by the high expression of APC, cyclin B1, PTTG, c-erbB2, and cyclin D1 in contrast to breast cancers without Paget's disease. Furthermore, the similar expression patterns of APC and APC regulatory proteins in both Paget's disease and underlying breast cancer support the epidermotropic theory as its pathogenetic mechanism.

The Difference of Cathepsin D Expression between Invasive Ductal Carcinoma and Ductal Carcinoma In Situ of the Breast.: Hye Kyoung Yoon, Soo Jin Jung; Korean J Pathol. 2004;38(6):408-414.

2,073 View
15 Download

Abstract PDF: BACKGROUND
It is known that cathepsin D expression in host stromal cells is associated with a more aggressive tumor behavior in breast cancers.
METHODS
Cathepsin D expression was examined in 222 cases of invasive ductal carcinoma (CA) and 25 cases of ductal carcinoma in situ (DCIS) by the immunohistochemical staining. Cathepsin D expression was evaluated according to the expression site, either in the tumor cells (CD-T) or in the stromal cells (CD-S), and graded according to the immunopositivity. The differences of CD-T and CD-S in each case were evaluated according to the pathologic parameters and estrogen receptor (ER)/progesterone receptor (PR) status.
RESULTS
The rate of CD-S was significantly higher in the CA than in the DCIS (p<0.0001). In the CA, the rate of CD-S was higher than that of CD-T, while in the DCIS, the rate of CD-T was higher than that of CD-S. In the CA, the rate of CD-S and the tumor grade showed a positive relationship (p=0.0281). There were positive correlations between the ER positivity and CD-S (p=0.0236), and between the PR positivity and CD-T (p=0.0246). For the DCIS, no significant relationships were noted between the pathologic parameters including ER/PR status and CD-T/CD-S.
CONCLUSION
Cathepsin D expression in the stromal cells seems to be related to the invasiveness and aggressive biological behavior in breast cancers. In addition, there might be some relationship betweeen the ER positivity and CD-S, and between the PR positivity and CD-T.

The Expressions of Tyrosine Kinase Receptors, EphA2, c-met and c-erbB-2 in the Human Breast.: Soo Kee Min, Hyun Deuk Cho, Seong Jin Cho, Hye Rim Park, Hyung Sik Shin, Young Euy Park, Bom Woo Yeom; Korean J Pathol. 2005;39(1):15-22.

2,092 View
23 Download

Abstract PDF: BACKGROUND
Tyrosine kinase receptor (TKR) is an important protein for normal-development, growth and tumorigenesis in human tissues. The purpose of this study was to evaluate the effect of TKR in the progression of breast cancer.
METHODS
The expressions of EphA2, c-met and c-erbB-2 were examined, by using immunohistochemical methods and RT-PCR, in samples of breast tissue that included 111 samples of normal epithelium, 34 samples of ductal carcinoma in situ (DCIS), and 109 samples of invasive ductal carcinomas (IDC). The results were compared with the prognostic parameters of breast cancer including the tumor grade, growth pattern, lymph node metastasis and the expressions of ER, PR, p53 and Ki-67.
RESULTS
The protein expressions of the three TKRs were higher in DCIS and IDC than in normal epithelium. The protein expression of EphA2 was correlated with a tumor grade, a labeling index of Ki-67, and the protein expression of c-met. Overexpression of c-erbB-2 was correlated with lymph node metastasis. The mRNA levels of the three TKRs were correlated with each other in normal tissue and IDC. The level of c-met mRNA was higher in the low grade tumors.
CONCLUSIONS
The three TKRs may play roles in the tumorigenesis of human breast cancer. The overexpressions of EphA2 and c-erbB-2 may be a poor prognostic parameter in breast cancers.

Tumor Angiogenesis and Cathepsin-D Expression in Invasive Ductal Carcinoma of the Breast.: Young Gyung Bae, Dae Hong Suh, Dong Sug Kim, Soo Jung Lee; Korean J Pathol. 1997;31(8):735-744.

2,054 View
17 Download

Abstract PDF: This study was conducted to assess the prognostic value of tumor angiogenesis and Cathepsin-D in breast carcinoma, by correlating them with other clinicopathologic prognostic factors. In order to estimate microvessels within the tumor, an immunohistochemical method using monoclonal antibodies for factor VIII-related antigens (DAKO-vWf, F8/86) was used, and they were counted (perx200 field) in the most active areas of neovascularization. For the expression of Cathepsin-D, an immunohistochemical method using monoclonal antibodies (Novocastra, NCL-CDm) was performed. The microvessel count ranged from 8 to 346 per x200 field and the mean (+/-SD) was 72.46+/-54.96. The microvessel count was correlated with the estrogen receptor status, and it was also correlated with the tumor size when it was graded into four groups (1-33, 34-67, 68-100, >100), but was not correlated with other clinicopathologic parameters. Cathepsin-D was expressed in 40% (46/115) of the cases, but it was statistically correlated with the tumor size only. In conclusion, the expression of Cathepsin D and the degree of angiogenesis in breast cancer showed a correlation with the tumor size only. Therefore, they do not appear to be good prognostic parameters, according to the present study.

Significance of c-kit and COX-2 Expression in Breast Tissue.: Eun Kyung Kim, Won Mi Lee, Jong Eun Joo, Sook Kyung Ko; Korean J Pathol. 2008;42(3):157-161.

2,216 View
21 Download

Abstract PDF: BACKGROUND
The proto-oncogene c-kit encodes a transmembrane tyrosine kinase growth factor receptor. Studies have shown that c-kit is highly expressed in normal breast epithelium, but expression is decreased in primary breast cancer. Cyclooxygenase-2 (COX-2) is an inducible enzyme that converts arachidonic acid to prostaglandins. Expression of COX-2 has been reported in malignant tumors including breast cancer. We evaluated the expression of c-kit and COX-2 in benign and malignant lesions of the breast to assess the roles of these proteins in cancer initiation and progression.
METHODS
We characterized 20 benign lesions, 20 intraductal carcinomas and 70 invasive breast carcinomas. Immunohistochemical staining for c-kit and COX-2 was performed.
RESULTS
Expression of c-kit was detected in 75% of the benign breast lesions, 40% of the intraductal carcinomas and 10% of the invasive carcinomas. COX-2 expression was observed in 80% of the benign lesions, 70% of the intraductal carcinomas and 52% of the invasive carcinomas. Expression of c-kit was significantly correlated with tumor size (p=0.02). COX-2 expression was significantly correlated with negative expression of estrogen receptor and progesterone receptor (p=0.02, p=0.04), Her-2/neu expression (p=0.008) and the high proliferation index (p=0.0002).
CONCLUSIONS
Our results suggest that c-kit and COX-2 might be involved in malignant transformation of the mammary epithelium and tumor progression. It is suggested that c-kit and COX-2 can be used as predictive markers and therapeutic targets.

S Phase Kinase Associated Protein 2 Expression in Breast Cancer and Its Prognostic Implications.: Eun Deok Chang, Eun Jung Lee, Se Jeong Oh, Chang Suk Kang; Korean J Pathol. 2005;39(2):69-73.

1,976 View
14 Download

Abstract PDF: BACKGROUND
S Phase Kinase Associated Protein 2 (Skp2), an F-box protein necessary for DNA replication, has recently been demonstrated to be an oncogene. The purpose of this study was to examine the Skp2 expression and to investigate its association with expressions of estrogen receptor (ER), androgen receptor (AR) and HER-2, as well as clinicopathological variables including tumor recurrence.
METHODS
The expressions of Skp2, ER and AR were examined by immunohistochemistry and HER-2 amplification by chromogenic in situ hybridization (CISH) in 117 cases of breast carcinoma.
RESULTS
Skp2 was expressed in 26 patients (22.2%) and was significantly correlated with tumor type (p=0.031), tumor grade (p=0.017) and ER expression (p=0.038). Twenty four (20.5%) of 117 patients had a tumor recurrence, and 6 patients (5.1%) died of multifocal metastases. Tumor recurrence was significantly correlated with histological grade (p=0.041) and lymph node status (p<0.001).
CONCLUSIONS
Although Skp2 expression was statistically insignificant in association with tumor recurrence, it might be useful as a biologic predictor in breast cancer. The simple and reliable immunohistochemical assay presented in this study can be a routine part of breast cancer evaluation and may influence patient management.

Analyses of Genetic Alterations in Breast Cancers by Comparative Genomic Hybridization.: Jin Man Kim, Young Mi Jeon, Young Hyeh Ko, Kyu Sang Song, Howe J Ree, Joo Seob Keum, Jae Hyuk Lee, Sun Hoe Koo; Korean J Pathol. 1999;33(8):603-613.

2,248 View
17 Download

Abstract PDF: Transformation and progression of breast cancer are thought to be caused by an accumulation of complex genetic alterations, but little is known about specific changes. In this study, the author has undertaken a genome-wide screening to detect genetic changes in 20 cases of breast cancer among Koreans, including 16 infiltrating ductal carcinomas, 2 medullary carcinomas, 1 invasive lobular carcinoma, and 1 borderline phyllodes tumor. Comparative genomic hybridization (CGH) was used to screen for DNA sequence gains and losses across all human chromosomes. Simultaneous immunohistochemical staining for c-erbB-2 (Her-2/neu), c-myc, cyclin D1, and p53 protein was done to make comparisons with nuclear grade and that with CGH results. Biotin-labeled tumor DNA and digoxigenin-labeled normal DNA were hybridized to normal metaphase cells. The fluorescence signals were captured by fluorescence microscope after detection by avidin-FITC and anti-digoxigenin rhodamine. Then, the ratio of fluorescence was calculated by an image analyzer. The immunohistochemical staining was done in paraffin-embedded tissue with an LSAB kit and avidin-biotin complex (ABC) method. The CGH results showed gains on chromosomes 8q (40%), 1q (30%), 17q (15%), 20q (15%), 18q (15%), 5p (15%), and 13q (15%). Deletions were on chromosomes 17p (45%) and 22q (20%). High-level amplifications (green/red ratio >1.5) were noted on chromosomes 1p31, 1q, 3q25-qter, 5p, 7q31-qter, 8q, 9p22-qter, 10p, 11p, 11q22-qter, 12p, 12q24, 14q21-qter, 15q23-qter, 17q, 18p, 18q12-qter, 20p, and 20q. By comparison with infiltrating ductal carcinoma, the two medullary carcinomas showed high-level amplification on chromosomes 1p31, 1q, 8q, 10p, 11p and 12p. c-erbB-2, c-myc, cyclin D1, and p53 protein expression was immunohistochemically detected in 9 of 20 (45%), 8 of 20 (40%), 10 of 20 (50%), and 13 of 20 (65%), respectively. The results indicate that the amplification on chromosome 8q, 1q and the deletions on chromosomes 17p and 22q are the most frequent genetic alterations in breast cancers among Koreans. The results reveal a different pattern of genetic alteration from previous studies. The CGH results were not correlated with the immunohistochemical profiles. The amplification pattern of medullary carcinomas was quite different from the pattern of infiltrating ductal carcinomas. The CGH was thought to be very useful in the screening of genetic alterations of solid tumors.

The Effect of Tamoxifen and Pentosan Polysulfate on the Microvessel Density and Cell Proliferation of Dimethylbenzanthracene-Induced Rat Mammary Carcinoma.: Chan Heun Park, Zhe Piao, Kwang Gil Lee; Korean J Pathol. 1996;30(2):94-105.

2,137 View
17 Download

Abstract PDF: Antiestrogen tamoxifen (TMX) is thought to elicit its therapeutic effect by competing with endogenous estrogens for the estrogen receptor. Several more recent studies asserted that the antitumor effect of TMX is not due solely to the inhibition of estrogen receptor-mediated action, but due partly to its capacity to inhibit angiogenesis and impair neovascularization. Despite extensive research and clinical experience with this drug, its exact mode of action in inducing tumor regression is still not clear. The present study is aimed toward the investigation of the effects of TMX on dimethylbenzanthracene- induced rat mammary carcinomas with respect to the tumor response to the drugs, histological changes, cell proliferative acitivity and angiogenesis inhibition, and if TMX has antiangiogenic action, to compare it with that of pentosan polysulfate (PPS), an already known antiangiogenic substance. Female Sprague-Dawley rats, aged 50 days, were divided into normal control, test control (tumor induction by dimethylbenzanthracene), TMX (TMX administration after tumor induction), and PPS (PPS administration after tumor induction) groups. Tumor response to the drug administration was classified according to changes of tumor volume as follows; complete response (CR), partial response (PR), no response (NR), and progressive disease (PD). The response rate of rat mammary carcinomas to the drug administration was significantly higher (p<0.05) in the TMX and PPS groups as compared with the test control group. There was, however, no statistical significance between the TMX and PPS groups. Necrosis was considerably frequent in tumors of the TMX and PPS groups. Hyaline change of the stroma was strikingly more common and marked in the TMX group and it was associated with atrophy of epithelial cells of the tumor glands. Proliferating cell nuclear antigen (PCNA)- labeling index of the tumors was significantly higher (p<0.05) in the tumors with NR and PD of the TMX group when compared with those with PR of the same group, which suggested a higher cell proliferative activity in these response groups. In the PPS group, however, there was no significant difference in PCNA index according to response. Microvessel density of the tumors was significantly lower (p<0.05) in the PPS group as compared with the test control and TMX groups and it was not related with response. The TMX group, however, did not show any significant difference in microvessel density when compared with the test control group. Microvessel density was significantly higher (p<0.05) in tumors with PD than those with PR in all 3 groups, which suggested a positive relation of increase in tumor size and angiogenesis. Based on these results it is thought that TMX and PPS inhibit growth of chemically-induced rat mammary carcinomas. It seems that the antitumor action of PPS is related with its antiangiogenic capability, but that of TMX does not have a relationship with angiogenenesis inhibition.

Comparative Study

A Comparative Study of PCNA Immunostaining, AgNOR Scores Hormone Receptors and Histology in Human Breast Cancer.: Eun Sook Chang, Kwan Kyu Park; Korean J Pathol. 1993;27(6):605-617.

1,935 View
11 Download

Abstract PDF: This study was performed on 50 cases of primary breast cancer removed surgically during the period 1990~1991 and compared the results of four morphologic methods developed for the detection of estrogen receptors, progesterone receptors, monoclonal antibody PCNA immunoreactivity, and the mean number of argyrophilic nucleolar organizer regions(mAgNORs) to ascertain the prognostic significance and also to detect highly malignant heterogenous cancer. To determine the validity of these measurements, a variance analysis was done with Kruskal-Wallis 1-way ANOVA. The results showed that the significant correlation between histologic grade and ER/PR status(P=0.005/P=0.015), the borderline significant correlation between mAgNORs and ER/PR status(P=0.08), and between AgNORs and stage(P=0.07), PCNA has no correlation with ER/PR status(P=0.25), clinical stage and histologic grade. In follow up, four cases of invasive ductal carcinoma with ER/PR, developed early and rapid metastasis within 2 years, three of them were classified as histologic grade 3 and another case was grade 2, whereas two of them were classified ans stage III(+) and the rest were in stage IIB(+) and stage IIA(-). The mAgNOR count of these four cases were ranged from 3.32 to 4.29 which were in the aneuploid category most likely. One of them had rather stormy rapid course with multiple organ metastases resulting death within one year. These results indicated that ductal carcinoma(>2cm size) with ER-/PR- and high mAgNOR level or high PCNA grade, and hihg histologic grade had h highly malignant course, marked by rapidly developing metastases. Thus we concluded that the status of ER/PR alone in tumor tissue is an important information for selecting hormone treatment btu, for the ultimate prognosis, is a weak indicator. Therefore for early detection of such heterogenous tumor, besides ER/PR, AgNORs or PCNA, histologic grade and tumor size are very useful as biological indicators of prognosis. The status ER/PR in combination with these indicators are more accurate and provide better basis on which to base a decision for early implementation of chemotherapy from which to give probably benefit by inhibition of rapid progress.

Original Articles

Analysis of Estrogen and Progesterone Receptors in Breast Carcinoma: Comparison of immunocytochemical assay with biochemical dextran-coated charcoal assay.: Ill Hyang Ko, Kyeong Mee Park; Korean J Pathol. 1996;30(3):228-237.

2,046 View
27 Download

Abstract PDF: Estrogen receptor(ER) is a soluble form of hormone receptor protein which is located in the nucleus and cytoplasm of a cell is found in 60% of cases of the cells of breast carcinoma. Fifty to sixty percent of ER positive breast carcinoma responds to antihormone therapy wheres the response rate is only 5% in ER negative tumors. Currently, the ER assay has become a standard index in the management and prediction of the prognosis of advanced breast carcinoma. Semiquantitative biochemical assay, dextran-coated charcol(DCC) assay, to measure ER from fresh tissue was first developed by Korenman in 1970 using isotope-labled ertradiol, has been widely utilized. In 1978, Kurzon newly developed immunocytochemical assay(ICA) employing monoclonal antibody against those hormone receptors to detect intracellular localization of ER and progesterone receptor (PR). The results of the assay have been reported by many investigators thereafter. The purpose of this study was to evaluate the hormonal receptors with a monoclonal antibody using an immunoperoxidase procedure to detect both estrogen and progesterone receptors (ER-immunocytochemical assay:ER-ICA and PR-immunocytochemical assay:PR-ICA) in 59 cases of paraffin embedded sections from formalin-fixed and routinely processed breast carcinoma tissue. Concomitantly, fine-needle aspiration biopsy cytology of the breast cancer from 29 women were assayed for ER/PR receptors. Results were compared with quantitative biochemical values determined from dextran-coated charcoal(DCC) assay on the fresh tumor tissue obtained subsequently from the surgery. ER-ICA showed positive result in 22 out of 36 DCC-positive cases(sensitivity, 61.1%) and negative in 23 out of 23 DCC-negative cases (specificity, 100.0%). PR-ICA was positive in 33 out of 35 DCC-positive cases(sensitivity, 94.3%) and negative in 16 out of 24 DCC-negative cases(specificity, 66.7%). The value of ER-ICA or PR-ICA positivity were roughly correlated with the concentration of ER/PR receptors analyzed by DCC method. The results of both methods were correlated with the nuclear grade of the tumor(ICA:p=0.002, DCC: p=0.015) but were not correlated with histologic grade(ICA: p=0.323, DCC: p=0.0164). ER-ICA positivity was correlated with lower incidence of axillary node metastasis (p=0.021) but no significant correlation between PR-ICA positivity and node metastasis(p=0.171). Both ER/PR-ICA positivity were not correlated with age(p=0.924) and tumor size(p=0.663). The score of ICA particularly ER was proportional to DCC level(ER: r=0.5, p=0.000, PR: r=0.2, p=0.000). ICA concordance with DCC of ER and PR were 76.3% and 83.1%, respectively. The concordance of PR-ICA and DCC was proportional but was statistically less significant. In aspiration biopsy cytology the concordance of ER/PR-ICA and DCC were 72.4% and 65.5%, respectively. Immunocytochemical staining to identify ER/PR receptors from the tissue of breast carcinoma would be tested as a mean to substitute for the conventional DCC method.

c-erbB-2 Oncoprotein Overexpression in Breast Cancer.: Tae Sook Hwang, Kyung Ja Cho, Young Bae Kim, Joo Ryung Huh, Ja June Jang; Korean J Pathol. 1994;28(1):1-7.

2,183 View
15 Download

Abstract PDF: c-erbB-2 oncogene is a normal cellular proto-oncogene coding transmembrane glycoprotein structurally similar to the epidermal growth factor receptor. Amplification of this oncogene in a variety of human adenocarcinomas has been reported and is particularly well documented in breast carcinoma. It has been suggested that amplification of this oncogene is indicative of poor prognosis and is valuable only second to the lymph node status. Using immunohistochemical staining for the c-erbB-2 protein, overexpression of this protein was analysed in 228 primary breast cancer specimens and the frequency of overexpression and the relationship between overexpression and the other established prognostic variables are evaluated. Ninty three cases out of 228 cases(40.8%) show postive oncoprotein overexpression and using the chi-squared test for a trend, a significant correlation was found between c-erbB-2 protein staining and the histological grade, lymph node status, and estrogen receptor status(P<0.05). No significant association was found between staining and the patient's age and tumor size. Most of the tumors with histological types known to have good prognosis showed negative expression. Above findings strongly suggest that expression of c-erbB-2 oncogene is another independent indicator of poor prognosis in breast carcinoma.

A Study on the Precancerous Lesion of Breast Carcinoma in 9, 10-Dimethyl-1, 2-Benzanthracene-treated Rats.: Cheon Sik Choi, Soo Min Kang, Hye Jung Lee, Gyung Hyuck Ko, Cheol Keun Park; Korean J Pathol. 1991;25(2):104-113.

1,945 View
13 Download

Abstract PDF: Following results were obtained from the light microscopic and stereomicroscopic observations of the breasts of rats treated with 9, 10-Dimethyl-1,2-Benzanthracene(DMBA). 1) Adenocarcinomas developed in 17 rats (24%) among 70 DMBA-treated rats. 2) Terminal and buds (TEB) were observed longer in DMBA-treated rats than in control group, but they finally disppeared 4 monthes after treatment. 3) Many hyperplastic alveolar nodules (HAN) developed in DMBA-treated rats. 4) There were no transitional lesions between TEB and adenocarcinoma or HAN and adenocarcinoma. 5) The number of lobules was decreased in DMBA-treated rats. On the other hand, terminal ducts were increased in number. These findings suggest that DMBA stimulate the regression of lobules and induce to form terminal ducts from which adenocarcinomas and HAN develop independently.

Expressions of E2F4 and E2F2 Transcription Factors in Breast Carcinoma.: Eun Young Kim, Hyun Jin Jo, Mi Ja Lee; Korean J Pathol. 2005;39(5):301-306.

2,606 View
39 Download

Abstract PDF: BACKGROUND
The E2F family (E2F1 to E2F6) of transcription factors plays a key role in cell cycle progression. Some act as oncogenes and others act as tumor suppressor genes (TSG) in a tissue-specific manner. E2F4 may function as a TSG. However, the role of E2F4 in breast carcinogenesis remains controversial. Also the clinical impact of E2F2 expression on breast cancer remains unknown.
METHODS
Expressions of E2F4 and E2F2 were assessed immunohistochemically in 113 breast carcinomas and were compared with clinicopathological variables, expressions of G1/S checkpoint proteins (p16, cyclin D1 and Rb), and DNA ploidy to identify their possible role and to assess their prognostic value in breast cancer.
RESULTS
Expressions of E2F4 and E2F2 were detected in 48 cases (42.5%) and 66 cases (58.4%), respectively. Expressions of E2F4 and E2F2 were significantly correlated with large tumor size (p<0.001) and lymph node metastasis (p<0.001). There was no correlation between expressions of E2F4 or E2F2 and any other variables, including age, histologic grade, DNA ploidy and expressions of p16, cyclin D1 and Rb.
CONCLUSIONS
These results suggest that expressions of E2F4 and E2F2 are associated with growth and spread of breast cancer and indicate poor prognosis.

Case Report

Secretory Carcinoma of the Breast: A case report.: Kyu Rae Kim, Jung Hyun Yang, Yeon Lim Seo, Howe Jung Ree; Korean J Pathol. 1996;30(4):347-350.

1,996 View
16 Download

Abstract PDF: We report a case of secretory carcinoma with axillary lymph node metastasis in a 21-year old woman. She was aware of a mass in her breast for 10 years and noticed a rapid growth of the preexisting mass during the last years. Histologically, the tumor was composed of micropapillary and microcystic or cribriform glandular structures which contained eosinophilic, mucinous, intraluminal secretions. The center had a dense hyalinized strama with a solid infiltrative growth of tumor cells with intracytoplasmic secretory vacuoles at the periphery. In addition, marked intraductal papillary epithelial proliferations were present at the superficial portions of the tumor near the nipple. Prognostic factors and their relationship to juvenile papillomatosis are discussed with a review of the literature.

Original Articles

Correlation of Expression of CD44, p53 and bcl-2 Protein, DNA Ploidy Pattern, and Clinicopathologic Prognostic Factors in Invasive Ductal Carcinoma of the Breast.: Mi Ja Lee, Ho Jong Jeon, Kweon Cheon Kim; Korean J Pathol. 1999;33(12):1152-1162.

2,037 View
25 Download

Abstract PDF: In this study of 64 cases of breast cancer with a clinical follow-up period of more than 5 years, several prognostic factors were evaluated. The purpose of this study was to determine whether any one parameter or group of parameters serves as adequate predictors of tumor behavior and patient's prognosis. Several prognostic factors included clinicopathological variables (patient's age, histologic grade, status of lymph node (LN) metastasis, and tumor size), expression of estrogen receptor (ER), progesterone receptor (PR), p53, bcl-2 and CD44 by immunohistochemistry, and DNA ploidy pattern. The results showed that the expression of ER and PR had a significant inverse correlation with the histologic grade (ER, p=0.05; PR, p<0.05). The expression of p53 protein showed a significant relationship with high histologic grade of tumor (p<0.05). The expression of bcl-2 protein was preferably seen in low histologic grade of tumor (p<0.05) and significantly associated with ER positive or PR positive tumors (ER, p<0.05; PR, p<0.05). This results suggest that bcl-2 protein might play significant roles in ER and PR. The CD44 expression showed a significant relationship with tumor size (p<0.05). The large size and aneuploidy pattern of tumor had a tendency to be associated with shorter patient survival. Cox's multivariate analysis showed that overall survival was affected by LN metastasis because of the shorter survival in patients with LN metastasis. In conclusion, tumor size, DNA ploidy pattern, and LN metastasis were themselves significant predictors of breast cancer survival rate.

An Immunohistochemical Study for the neu and ras Oncoprotein and Epidermal Growth Factor Receptor in the Breast Carcinoma.: Jeong Ja Park, Tae In Park, Tae Joong Sohn, In Soo Suh; Korean J Pathol. 1994;28(2):126-134.

1,939 View
11 Download

Abstract PDF: To evaluate correlation between the expression of neu and ras oncoprotein and epidermal growth factor receptor on breast carcinoma and other known prognostic factors, immunohisto-chemical studies were performed. Positive reaction for neu, which appeared as brown granular deposits along cell surface and cytoplasm of the tumor cells, was significantly correlated with the histological grade but not with other prognostic factors such as tumor size, lymph node me-tastasis, local recurrence, and estrogen and progesteron receptor status. Also granular deposits of ras were noted in the carcinoma cells in the cytoplasm, while the epithelaial cells of the normal lobule and duct showed negative reation. But expression of ras was not significantly associated ras with other prognostic factors. The reaction for EGFR was mostly negative on epithelial cells of both the normal lobule and duct, and was not significantly associated with other prognostic factors. The results suggested that expression of the neu oncoprotein is significantly associated with the histological grade of breast carcinoma, while the ras and the EGFR do not show significant prognostic value.

Expression of p34(cdc2), p27(Kip1), p21(WAF1/Cip1) and p53 in Human Breast Cancers.: Dong Hoon Kim, Chan Kum Park, Ho Jung Lee, Won Mi Lee, Eun Kyung Kim, Jong Eun Joo; Korean J Pathol. 2005;39(6):391-400.

2,171 View
17 Download

Abstract PDF: BACKGROUND
Cell cycle progression is governed by cell cycle regulators and inhibitors such as the cyclin dependent kinases (CDK), p27(Kip1), p21(WAF1/Cip1) and p53. The purpose of this study was to correlate expressions of p34(cdc2), p27(Kip1), p21(WAF1/Cip1) and p53 with the various clinicopathologic prognostic parameters of human breast cancers.
METHODS
The paraffin-embedded tissue sections from 102 patients with human breast carcinomas were examined by performing immunohistochemical staining. The primary antibodies used for immunohistochemical staining were mouse monoclonal antibody to human p34(cdc2), p27(Kip1), p21(WAF1/Cip1), p53, ER and PR.
RESULTS
The expression rates of p34(cdc2), p21(WAF1/Cip1) and p53 were 29.3%, 40.2% and 49.1% in breast carcinomas, respectively. In normal breast tissues, p34(cdc2), p21(WAF1/Cip1) and p53 were not expressed. The p34(cdc2) was expressed in the cytoplasm of cancer cells. The expression rate of p27(Kip1) was 29.3% in breast carcinomas and 100% in normal breast tissues, so the loss of p27(Kip1) expression in breast cancer was noted. The high expression of p21(WAF1/Cip1) in neoplastic cells was associated with the p53 expression (p=0.03). The expression of p27(Kip1) was correlated with that of the progesterone receptor (PR) (p=0.04) and the expression of p21(WAF1/Cip1) was correlated with that of positivity for estrogen receptor (ER) (p=0.04) and PR (p=0.04). No correlation was demonstrated between the mean patient survival and the expression rate of p34(cdc2), p27(Kip1), p21(WAF1/Cip1) and p53.
CONCLUSIONS
The loss of the normal cell growth cycle by the abnormal expression of cyclin dependent kinases and their inhibitors and the steroid hormones may play an important role in human breast carcinogenesis. The p53 dependent p21(WAF1/Cip1) pathway, the p27(Kip1) protein loss and the cdc2 overexpression were important in development and progression of human breast cancer.

Expression of the pS2 Protein and Its Relation with Estrogen and Progesterone Receptor in Breast Cancer.: Eun Deok Chang, Chung Soo Chun; Korean J Pathol. 1998;32(3):169-173.

2,354 View
18 Download

Abstract PDF: Expression of the pS2 protein in breast carcinoma is a useful guide to evaluate the prognosis and response to tamoxifen. The pS2 protein is an estrogen-regulated 60 amino acid protein which was originally discovered following the screening of cDNA libraries in MCF-7 breast carcinoma cells and is induced through estrogen-dependent transcription of the pS2 gene. The presence of the pS2 protein in breast cancer is considered as valuable as the receptor status, or even more so, in predicting the response to hormonal therapy. We have investigated the pS2 protein expression in 62 cases of primary breast cancer in order to know the relationship between the expression rate of the pS2 protein and hormonal receptor status using immunohistochemical procedures on formalin-fixed and paraffin-embedded tissues. Concomitantly, both the estrogen receptors (ER) and progesterone receptors (PR) were examined using the immunohistochemical technique. Positive staining for the pS2 was seen in forty-nine cases (79%) of the tumors. Forty three cases (88%) of the pS2 positive tumors were ER positive and forty one cases (84%) of the pS2 positive tumors were PR positive ; forty six cases (93%) of pS2 positive tumors were positive for ER and/or PR. The pS2 status correlated significantly with the ER (p<0.0001) and PR (p<0.001). The results reveal a close association between the pS2 protein and either or both the ER and PR status.

Pathologic Study of Breast Cancer in Korea.: Sang Kook Lee, Gyung Hyuck Ko; Korean J Pathol. 1987;21(4):257-266.

2,116 View
13 Download

Abstract PDF: From a retrospective study of 366 cases of breast cancer, following results are obtained. 1) Relative incidence of breast cancer is increased during recent 7 years as compared with total female cancer. 2) Invasive ductal carcinoma and invasive ductal carcinoma with a predominant intraductal component (ICPI) account for 78% of total breast cancer, and its ratio shows little variance during recent 7 years and as compared with previous studies. 3) The incidence of invasive lobular carcinoma is increased as compared with 10 years ago, but it seems more likely that the increase is due to difference in diagnostic criteria rather than due to real increase in incidence. 4) The average patients' age of five major histologic types of breast cancer is 47.3 year. The patient's age of invasive ductal carcinoma is highest and that of ICPI is lowest. 5) Outer upper quadrant is the most frequent site of breast cancer. Left side is slightly more frequent than right side. There is little variance among the histologic types in tumor location. 6) The average symptom duration of patients of major types of breast cancer is 8.4 month. It is longest in invasive ductal carcinoma and shortest in ICPI. 7) Invasive lobular carcinoma is largest in tumor size and intraductal carcinoma is smallest, among the major histological types. 8) Intraductal carcinoma is most freqnently accompanied by nipple discharge and Paget's disease. 9) The rate of axillary lymph node metastasis is highest in invasive lobular carcinoma, followed by invasive ductal carcinoma, medullary carcinoma, and ICPI, in order of freqnency. 10) Distant metastasis is to the bone, lung, liver and brain, in order of freqnency. Medullary carcinoma shows the highest rate of distant metastasis. 11) The important prognostic factors of breast cancer are histologic types, status of axillary lymph node metastasis, size of tumor and histologic grade of malignancy. But there is little difference in prognosis between invasive ductal carcinoma and medullary carcinoma.

Assessment of DNA Ploidy, Estrogen and Progesterone Recetor Status and Her-2/neu Oneoprotein Expression in Breast Carcinoma by Image Analysis.: Ae Ree Kim, In Sun Kim, Kap No Lee; Korean J Pathol. 1994;28(3):246-259.

2,046 View
10 Download

Abstract: In 41 cases of breast cancers, the aneuploidy measured by Image Analyzer was compared with that of flow cytometric analysis, and estrogen and progesterone receptor(ER/PR) and Her-2/neu oncoprotein were immunohistochemically stained and measured by Image Analyzer. In ER/PR, the positive nuclear area(PNA, %) was measured, and in Her-2/neu, the content of oncoprotein was expressed as pg/cell. To assess the usefulness of these parameters as a prognostic factor, the author evaluated the results in relation with tumor size, nuclear grade and lymph node metastasis. The obtained results are summarized as follows: 1) The detection rate (90%) of aneuploidy by image analysis was higher than that (70%) of flow cytometric analysis. The concordance rate of both method was 80%. 2) The positivity of ER was 73% and PR was 34%, and the high PNA of ER and PR was related with high nuclear grade. There was an inverse correlation of the ER PNA with tumor size and PR PNA with negative lymph node. 3) Her-2/neu oncoprotein overexpression was found in only 2 cases and another two showed borderline overexpression. All four cases had DNA tetraploidy. From the above results, it was concluded that the image analyzer could be used in DNA analysis and in quantitation of immunostained ER/PR and Her-2/neu oncoprotein, providing the important information in the management of the breast cancer patients.

Morphologic Changes of the Parenchymal-Stromal Junction in Infiltrating Duct Carcinoma of the Breast: Immunohistochemical and Ultrastructural Features of Myoepithelial Cell, Basement Membrane.: Min Cheol Lee; Korean J Pathol. 1988;22(1):42-56.

1,976 View
12 Download

Abstract PDF: The morphologic study of noninfiltrating and infiltrating duct carcinoma of the breast disclosed profound alterations along the parenchymal-stromal junction. But fate of myoepithelial cell, changes of basement membrane and the relationship of fibroblast to myofibroblast remain uncertain. To study the morphologic changes of myoepithelial cell, basement membane and stromal fibroblast, a series of 32 not otherwise specified (NOS) type of infiltrating duct carcinoma of the breast with regional lymph node metastases was examined light microscopically after S-100 protein immunoperoxidase staining by biotinavidin system (BAS) and ultrastructurally. The results were as follows. 1) In 18 out of 32 cases, S-100 protein positive myoepithelial cells were observed individually in the parenchyma at the periphery of some carcinomatous duct-like structures or cancer cell nests. The cells were noted in 7 cases of metastatic regional lymph nodes. In 5 cases contained with 2 cases of infiltrating duct carcinoma with focal sarcomatous metaplasia, S-100 protein positive cells were seen in fibroblast-like spindle cells in stroma adjacent to cancer nests. 2) Ultrastructural features of myoepithelial cells showed significant loss of fine microfilament and hemides-mosomes and relative imcrease of coarse large filaments. Morphologic transformation of myoepithelial cells to neoplastic epithelial cells or stromal fibroblast-like spindle cells were suggested in 3 NOR type and 2 metaplastic type carcinomas. 3) The ultrastructural changes of basement membrane disclosed some variations from case to case and even within a single tumor if large number of blocks were studied. Focal destruction, splitting, segmentation and extensive loss of basement membrane arround cancer nests were noted. On the other hand, basement membrane material surrounded cancer nests or individual cancer cells irregularly. 4) Most stromal fibroblasts in infiltrating duct carcinoma had abundant rough endoplasmic reticulum with enlarged plump cytoplasm. Some of them were transformed to myofibroblasts which had perinuclear rough endoplasmic reticulum and peripheral microfilaments with dense bodies in their cytoplasm.

Subcellular Localization of p27(kip1) in Breast Cancer and Its Prognostic Significance.: Sook Hee Hong, Dae Choel Kim, Se Heon Cho, Young Seoub Hong; Korean J Pathol. 2006;40(3):185-192.

2,151 View
22 Download

Abstract PDF: BACKGROUND
p27 is a member of the cyclin-dependent kinase (CDK) inhibitors that arrest the progression of the cell cycle; thus, it acts as a tumor suppressor gene. The loss or decrease of p27 protein is frequently seen and this has an independent prognostic potential for many human cancers. p27 is functionally inactivated through accelerated proteolysis and cytoplasmic sequestration. Cytoplasmic mislocalization of p27 by abnormal phosphorylation in the tumor cells doesn't allow it to bind and inhibit nuclear cyclin/CDK targets.
METHODS
We examined the p27 protein expression in 86 cases of invasive ductal carcinoma of the breast via immunohistochemical staining to evaluate the subcellular localization of p27 and its relationship with the clinicopathologic features and the prognostic factors.
RESULTS
The nuclear expression of p27 was noted in 48.9% of the tumors, a combined nuclear and cytoplasmic expression was noted in 20.9%, a cytoplasmic expression was noted in 12.8%, and a negative expression was noted in 17.4%. The decreased nuclear expression and/or cytoplasmic mislocalization of p27 were statistically correlated with the nuclear grade (p=0.001), histologic grade (p=0.036), tumor size (p=0.033), lymph node metastasis (p=0.043), ER (p=0.001), and PR (p=0.001) status, while they were not correlated with patient age, stage, HER2, p53, and Ki67.
CONCLUSIONS
The breast tumors showing both decreased nuclear expression and cytoplasmic mislocalization of p27 are associated with a deranged cell cycle via functional inactivation and also with poor prognostic factors. It is expected that p27 can be a promising anticancer target molecule for the treatment of breast cancer.

Relationship between Immunohistochemical Expression of Cathepsin D and Other Prognostic Factors of Breast Carcinoma.: Kwang Hwa Park, Byeng Woo Park, Kyong Sik Lee, Kwang Gil Lee; Korean J Pathol. 1994;28(6):612-619.

1,942 View
20 Download

Abstract PDF: The cathepsin D is a lysosomal protease secreted in excess by breast cancer cells. The function of this enzyme is degradation of the extracellular matrix and proteoglycan. It is induced by estrogens in estrogen receptor positive breast cancer cell lines. On the basis of this, cathepsin D expression in breast cancer cells seems to be correlated with the prognosis. But there is debates in its prognostic significance. Relationship between cathepsin D expression and other prognostic factors of breast cancer was studied. We investigated 51 cases of invasive ductal cell carcinoma of breast removed by open biopsy or mastectomy. All cases were fixed in formalin and embedded in paraffin. We used 46-KD intermediate form of the enzyme for cathepsin D expression on immunohistochemical stain. We observed no significant correlation with age, stage, histologic grade, lymphatic invasion, and estrogen receptor status. Cathepsin D may be an independent factor which is not related with other prognostic factors, especially estrogen receptor status.

KAI-1 Protein Expression in Breast Cancer: Correlation with Axillary Lymph Node Metastasis and other Prognostic Factors.: Shi Nae Lee, Min Sun Cho, Sun Hee Sung, Hea soo Koo, Ok Kyung Kim, Woon Sup Han; Korean J Pathol. 2003;37(4):239-245.

2,474 View
42 Download

Abstract PDF: BACKGROUND
KAI-1 is a metastasis suppressor gene. We have evaluated the correlationbetween KAI-1 protein expression in ductal carcinomas of the breast and axillary lymph nodemetastasis.
METHODS
The expression of KAI-1 protein was confirmed by immunohistochemistryto examine breast tissues of ductal carcinomas from 50 patients with nodal metastasisand from 53 patients without metastasis. Western blot analysis was performed on fresh frozenbreast tissues from 17 cases with nodal metastasis and from 19 cases without metastasis.
RESULTS
Immunohistochemical KAI-1 protein expression was decreased or negative in 39out of 50 cases with metastasis (78%), compared with 8 out of 53 cases with no metastasis(15.1%). The difference was statistically significant (p<0.05). Immunohistochemical KAI-1protein expression was significantly decreased in cases with higher modified Black's nucleargrade (p=0.027) and larger tumor size (p=0.039). Western blot analysis showed positivebands at 29.5 kDa in 8 out of 19 cases without metastasis (42.1%), and none of the 17 caseswith metastasis showed positive bands (p=0.0024).
CONCLUSION
These results suggest thepossibility that KAl-1 might play a major role of a metastasis suppressor gene in addition tothe part it plays in the growth and progression of human breast ductal carcinoma. In addition, the decreased expression of KAI-1 protein in breast ductal carcinomas could be used as afactor suggesting poor prognosis.

Reduced Expression of Claudin-7 Correlates with Invasiveness and Nuclear Grade of Breast Carcinomas.: Sang Hee Seok, Su Hwan Kang, Soo Jung Lee, Tae Yoon Hwang, Young Kyung Bae; Korean J Pathol. 2007;41(3):158-164.

2,045 View
20 Download

Abstract PDF: Background
: Claudins are important components of the tight junctions in the intercellular barriers and cell polarity. Among them, claudin-7 is down-regulated in breast cancers compared with the normal breast epithelium. The aim of this study was to determine the expression pattern and prognostic value of claudin-7 in breast carcinomas.
Methods
: Claudin-7 expression was evaluated immunohistochemically in 42 cases of ductal carcinoma in situ (DCIS) and in 142 cases of invasive breast carcinoma (IBC) using a tissue microarray (TMA).
Results
: Claudin- 7 was strongly expressed in the normal luminal epithelial cells in the breast lobule. The level of claudin-7 expression was significantly lower or absent in 45.2% (19/42) of DCIS and 72.5% (103/142) of IBC. A loss or reduced expression of claudin-7 correlated with the invasiveness (p=0.001) of breast carcinomas and a high nuclear grade (p=0.013) in IBC.
Conclusion
Claudin-7 is an important tight junction protein in the breast and a loss of expression may assist in the dissociation and invasion of tumor cells.

First
Prev
Page of 1
Next
Last

Search